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The ineffective delivery of genes and drugs have become a big obstacle for the treatment of cancer,
due to either poor stability or low aqueous solubility. In the first part, A ROS responsive polymer
named poly(ethylene glycol)–poly[aspartamidoethyl(p-boronobenzyl)diethylammonium bromide]
(PEG-B-PAEBEA) was developed for codelivery miR-34a mimic and small molecule PLK1
inhibitor volasertib (BI6727) for the treatment of pancreatic ductal adenocarcinoma (PDAC), since
tumor suppressor microRNA-34a (miR-34a), which targets many oncogenes related to proliferation,
apoptosis, and invasion is significant downregulated while Polo-like kinase 1 (PLK1) closely
associated with short survival rates of pancreatic cancer patients is remarkably upregulated . In part
2, due to increased number of cancer stem cells (CSCs), a pH and glutathione (GSH) sensitive
delivery system, fabricated by DTX and a pH responsive diisopropylamino ethanol and GSH
responsive RUB prodrug conjugated polycarbonate DTX loaded P-RUBs (DTX/P-RUBs), was
developed to overcome the chemoresistance by targeting both of tumor bulk cells and CSCs.
Rubone (RUB) is a miR-34a activator which is downregulated in CSCs. Fast release of DTX and
RUB in the cytoplasm after endocytosis could upregulate the intracellular miR-34a, which then
affected the expression of proteins involved in chemoresistance, thus sensitizing the tumor cells
towards DTX and further leading to significant inhibition of TXR tumor progression. Thus, DTX/PRUBs has the potential to treat TXR prostate cancer. By taking advantage of this dual responsive
strategy, the successful delivery of many other hydrophobic drugs can be achieved for cancer
treatment.
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Chapter I
Introduction
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1.1 Cancer and its microenvironment
Cancer has become the leading cause of death worldwide, accounting for around 9.6 million
deaths in 2018 [1]. Patients who have cancer often show a lump, abnormal bleeding, prolonged
cough, unexplained weight loss etc. Cancer is a collection of diseases (over 100 types) that are
known for uncontrolled cell division, immortality and abnormal microenvironment, including
prostate cancer, pancreatic cancer, liver cancer, medulloblastoma, etc [1]. Cancer cells proliferate
and grow into tumor (an abnormal cell mass) and hematologic cancer, in which the cancer cells
spread among the blood, lymph systems and bone marrow [2]. Malignant tumor can spread into or
invade nearby tissues, with some cancer cells breaking off from the original disease site and
traveling to distant parts by taking advantages of blood stream or the lymph system, forming new
tumors [3].
Cancers start when genetic changes affect the natural orderly process. They are mainly caused
by genetic mutation of oncogenes that induce cell proliferation and differentiation, and cancer
suppressor genes that inhibit cell growth or stimulate apoptosis by the alteration of intracellular
signaling pathway from environmental and lifestyle factors (tobacco, radiation, pollution, obesity
infections, etc.) [4-7]. It is often hard to postulate what factors may lead to the onset of cancer
because the oncogenic causes do not have specific fingerprints. The genetic change in cancer cells
is clonally bias to aberrant cell division, lack of excessive growth inhibition, immune system
avoidance, cell death transmission blockade and genetic materials error accumulation [8, 9].
Heterogeneity is another feature of tumors that even tumors cells within the same tumor site may
have different genetic mutations. This great genetic diversification that different cancer cells may
have different genetic changes consists of one of the fundamental difficulties for the cancer
treatment [10-12]. In the following sections, we will mainly focus on solid tumors, rather than other
categories of cancers (leukemia, lymphoma, sarcoma and melanoma).
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The tumor and its microenvironment are closely associated and interacted. By influencing the
normal cells, immune cells and blood vessels with released extracellular signals and promoted
angiogenesis, cancer cells can generate a tumor microenvironment that favor the growth of tumors
by providing nutrients and oxygen, removing wastes and evading the immune system [9, 13].
Most of cancers are not well vascularized due to uncontrolled cell proliferation. As a result, the
blood vessels formed in the tumors differ from the one in other normal tissues. The permeable
vasculature is thought to have insufficient pericytes and a malformed basement membrane [14, 15].
The leaky vasculature opens a door for large molecules and particles with a size, ranging from 10
to 500 nm to accumulate in the tumor, ensuring high demand of nutrient and oxygen supply for
rapid tumor growth [16, 17]. This phenomenon is well defined as the enhanced permeability and
retention (EPR) effect. Nonetheless, EPR effect also provides us with an increasing promising
paradigm for tumor targeting and anticancer drug developments through its unique facilitated
accumulation of macromolecules given that normal tissues have intact vasculature.
The rapid growth of tumor can contribute to the overall hypoxia in tumors because the interior
of the tumors become distant from the blood vessels and more cancer cells from high cell
proliferation demand more oxygen and nutrients than before, which cannot be compensated by
angiogenesis [18, 19]. Being underfed, the cancer cells are more genetically instable. Hypoxiainducible factor 1 (HIF-1), a key regulatory transcription factor, is also upregulated on account of
hypoxia. HIF-1 is responsible for adaptive cellular changes. For example, it is found to influence
glycolytic genes that take effect in reduction of oxygen consumption and availability. HIF-1can
also contribute to increased cell migration and extracellular matrix (ECM) remodeling [18, 20].
Hypoxia can lead to the change of metabolism in cancer cells to aerobic glycolysis, where this
process produces lactate from glycose. This switch generally resulted from the tumor cells fast
metabolism and proliferation as discussed above to meet the high energy supply. To remain the
neutral intracellular pH value (7.2-7.4), cancer cells will continuously excrete the generated lactate,
leaving the extracellular tumor microenvironment acidic (pH 6.5-6.9). In addition, the CO2
3

produced from respiration of a surging population of cancer cells exacerbate the acidic tumor
microenvironment [21, 22]. It was reported that the acidic microenvironment will induce the
degradation of ECM to facilitate the migration of cancer cells.
About 20 years ago, tumors were first described as wounds that do not heal by H.F Dworak
[23]. Different types of cells and some other non-cellular components, including ECM and soluble
factors coexist in tumors. Cancer stem cells (CSCs) are a type of cancer cells that possess the ability
of self-renewal and differentiation into any cells in the overall tumor population. They are generally
quiescent, making it more resistant to chemotherapy. Thus, treatment of cancer that fails to
eradicate the CSCs inevitably gives rise to the tumor relapse after a chemotherapy-induced
remission [24, 25]. By targeting both tumor bulks cells and CSCs, we can expect a more effective
cancer therapy that reduce the risk of relapse and metastasis.
Cancer-associated fibroblasts are another type of predominant cells in tumors, which originate
from normal cells that closely interact with tumor cells [26, 27]. They are responsible for the
synthesis of a variety of components in ECM, including fibronectin, collagen and some proteases
for ECM remodeling [28, 29]. In order to construct friendly microenvironment for the rapid tumor
growth, cancer-associated fibroblasts synthesized and secrete various factors, including vascular
endothelial growth factor (VEGF), fibroblast-activation proteins (FAP) and α-smooth-muscle actin
(α-SMA), etc., which are found to be critical for tumor angiogenesis and metastasis [28, 30, 31].
Therefore, the therapeutic intervention for targeting both cancer-associated fibroblasts and cancer
cells are promising in antitumor therapy.
Infiltrating inflammatory cells that exhibit pro-tumorigenic phenotype also exist in the tumor
microenvironment, including macrophages, lymphocytes, leukocytes, neutrophils and dendritic
cells [9, 32]. They are shown to favor angiogenesis, lymphocytes function inhibition, the tumor
growth, and metastasis by producing multiple cytokines, chemokines and enzymes (matrix
metalloproteinases (MMPs), cysteine cathepsin proteases) [33]. These cells can not only survive in
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hypoxic tumor microenvironment, but also take part in the formation of the hypoxic tumor
microenvironment by overproduction of reactive oxygen species (ROS) that acts through NF-kB
signaling pathway [34]. With its contribution to the establishment of an inflammatory milieu,
tumors are well nourished and rapidly expanded.
Endothelial cells and pericytes play an important role in supporting high amount of oxygen and
nutrients for tumor growth as they mainly compose the blood vessels [35]. Tumor growth
necessitates angiogenesis and prolongation of the pre-existing capillaries, which is mediated by the
proliferation and migration of endothelial cells. Pericytes that surround the outer side of blood
vessels are structural support for endothelial cells [36, 37]. Due to the high demand of blood supply
in tumors, blood vessels are formed at a relatively high speed. As a result, the balance between
pericytes and endothelial cells may be impaired, giving rise to malformed vasculature with gaps
for EPR effect [38, 39].
Besides the cells, non-cellular components in the tumor microenvironment also contribute to
the controlled outgrowth of tumors. ECM is a well-organized network constituted by a large variety
of matrix macromolecules, such as collagens, elastin, fibronectin (FN), laminins, glycoproteins,
proteoglycans [40-42]. Interstitial ECM and pericellular ECM are the 2 main types of ECMs. The
basement membrane is one of pericellular ECM that hold the parenchyma and connective tissue
together, preventing them from ripping apart [43]. In addition to providing support, ECM also
segregates tissue from one another and regulates intercellular communication (cell crosstalk). The
porous, relaxed and relative “soft” ECM creates a favorable environment for tumor cells and
stromal cells [41].
MMPs are a group of zinc-dependent endopeptidases that participate in a variety of
physiological processes [44, 45] . They are shown to mediate the ECM degradation, thus breaking
down the histological barrier of the basement membrane and resulting in the cancer cell invasion
and metastasis. Recent insights gained by MMPs regulated processes demonstrate that MMPs affect
growth signals, regulate apoptosis and involve in tumor angiogenesis [46].
5

Integrins are the cell membrane receptors that are highly expressed on multiple cells in tumors
[47]. They act to anchor cells by mediating adhesion of cells through its two subunits (αv and βv)
by linking cytoskeleton with ECMs. Integrins can bidirectionally signal the information either from
ECM to cell interior (outside-in) or from cell interior to the outside of tumor cell (inside-out). Until
today, several integrins are identified with tumor initiating and promoting ability [48, 49].
Meanwhile, chemokines, cytokines and other soluble factors overexpressed by tumors cell and
other types of cells act on a series of signaling pathways by binding to their relating receptors [5052]. Transforming growth factor-β (TGF-β) induces the epidermal to mesenchymal transition
(EMT), promoting tumor metastasis [53]. As discussed above, the overproduction of VEGF and
fibroblast growth factor (FGF) also stimulates tumor angiogenesis [54]. The secretion of IL-10 by
the tumor-associated macrophages (TAMs) can inhibit lymphocyte functions for immune escape
[9].
To this end, and the non-cellular components constitute a supporting scaffold for the tumor
growth as well as expansion.

1.2 Current Managements of Cancer
Current therapeutic strategies of solid tumors include surgery, chemotherapy, radiation,
immunotherapy, laser therapy, etc. Surgery and radiation are valuable tools, but only applicable to
the local non-metastatic cancer. As desirable treatments for cancer need to spread over to every
corner of human bodies, drugs including small molecules and macromolecules (DNAs, RNAs,
peptides and proteins) and immune-mediated therapy become fascinating to scientists.
Chemotherapy is old but still a dominant approach to intervene the tumor progression. It was first
applied for tumor treatment about 70 years ago when scientists observed tumor regression after the
administration of the nitrogen mustard [55, 56]. Though effective, chemotherapy still has some
notorious side effects such as nausea, diarrhea and alopecia due to indiscriminate cell destruction.
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Nonetheless, chemotherapy evolved to effective treatments for both of hematological cancers and
solid tumors, with the successive approval of a series of chemotherapeutic agents by Food and Drug
administration (FDA) such as antifolate drugs, methotrexate, paclitaxel and cisplatin because it was
once for many years only approach for metastatic cancer [57-59]. Thus, many efforts were devoted
to discovering more potent drug candidates, among which a few drugs were approved since many
of them failing to meet the Lipinski's rule of five, within which the moderate solubility requirement
inhibits the further application of many of potent drug candidates. Immunotherapy has long been
pursued and is recently emerging as a very promising method to treat tumors. It stimulates and
improves the host own immune system to fight tumors with the stunning positive results for the
antibody application of anti-programed death (anti-PD1) and anti-cytotoxic T lymphocyte antigen
4 (anti-CTLA-4) in humans [60-64]. Despite the encouraging advances achieved in immunotherapy
today, the chemotherapeutic drugs are still the mainstay of most cancer treatments by dominating
the pharmaceutical market due to low cost, wide range of application, relatively mild side effects,
etc. Gene therapy is another potential and fascinating strategy to treat tumors by counteracting or
replacing malfunctioning genes within the cell because its fundamental goal is to modulate the
mutated gene expression of specific cells which are the root for the progression of tumors [65, 66].
However, hurdles to realize this concept that sounds simple are dauting when are put into practice.
Genes must travel across multiple complex tissue, blood vessel and cellular barriers to deliver the
new genetic information to target cells, which accordingly overexpress specific molecules to
correct the abnormal conditions without disrupting essential cellular activities. In order to sustain
the benefits of gene therapy, the cells, being able to transmit the gene correction to their daughter
cells that possess same ability as parent cells, must proliferate to a certain large number, escape
capture by immune system and survive in a long term [66]. In this case, drawbacks that are known
for gene therapy need to be overcome. For example, given the low transfection efficiency due to
large size and negative charge of these macromolecules, the introduction of them to the interior of
cells for implementing their function needs mediating by viruses [67]. The immunogenicity can be
7

overcome by complexing with non-viral large molecules [67]. Chemical modification can be used
to improve the stability and enhance the selectivity of genes. [68, 69]. In spite of the challenges, a
small interfering RNA-based drug named Patisiran was approved by FDA in 2018 for the treatment
of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis, which seems to
bring a flourish spring in the development of gene therapy by non-viral delivery system that is less
problematic than viruses [70].
Though effective and promising, chemotherapy, immunotherapy and gene therapy are either
toxic and mortal or non-specific. Therefore, highly selective and effective therapeutic strategies to
improve cancer treatments are highly desirable.

1.3 Nano-Sized Drug Delivery Systems
Nano-sized drug delivery systems (NDDS) provide an alternative approach to resolve the
problems facing by the aforementioned therapies. NDDS are generally thermodynamically stable
nanoscale delivery systems, with a size less than 200 nm for better penetration as well as avoidance
the recognition of mononuclear phagocyte system (MPS) and reticulo-endothelial system (RES)
when traveling in bloodstream [71, 72], and are capable of loading chemotherapeutic agents (small
molecule drugs) or macromolecules (genes, peptides and proteins) into their core [73]. From this
perspective, NDDS not only solve drug related problems by solubilizing the hydrophobic but potent
drug candidates and complexing with genes to avoid the use of virus that can cause potential
carcinomas and immunogenicity, but also improve the pharmacokinetic profiles of the drugs via
protecting drugs from fast degradation, reducing the renal clearance and thus prolonging the blood
half-life of the drugs [74, 75]. The heterogeneity of tumors undoubtfully does not allow a “one fits -all” approach that one nanomedicine can be applied in various cancers. NDDS are nevertheless
a wonderful and versatile delivery platform that can be customized to successfully overcome
complex physiological barriers to tumors and further effectively transport into the cells [76]. Given
the “leaky” property of vasculature and lack of lymphatic drainage in tumors, NDDS can
8

preferentially accumulate in the diseased sites via EPR effect, resulting in regionally much higher
concentration of biologically active drugs than in normal tissues, thus as an indirect approach
reducing system toxicity of the free drugs [39, 77]. Active targeting can also be achieved by
attaching either natural or synthetic ligands of specific receptors overexpressed on the tumor cells
onto the surface of the nano-sized particles, such as small molecules, antibodies, or their fragments,
peptides and growth factors [78].
In addition to the application of therapeutic delivery, NDDS can also be developed for
diagnostic purpose, where the NDDS allow the detection in molecular scale for the identification
of abnormalities including disease markers, precancerous cells and fragments of viruses. In the
following section, we will mainly focus on the therapeutic application of NDDS.
NDDS are mainly composed of either polymer-therapeutic molecules conjugates (small
molecule drug, gene, peptides and proteins) with chemical bond linkage between the polymers and
therapeutic molecules, or particulate drug carriers with the therapeutic agents physically loaded
within the assemblies of different structures made from polymers (micelles, dendrimers and
nanoparticles), lipids (liposomes), metals (gold, Fe2O3, and MnO2), silica and organometallic
compounds (carbon nanotubes) [79, 80]. Several of them have been approved for clinical use, such
as Doxil, Abraxane, Marqibo, MM-398.

1.4 Smart Delivery of Drugs and Genes
Given the improvement of pharmacokinetic profile and aqueous solubility of therapeutic agents
brought by NDDS， NDDS are promising in taking conventional therapies to a new era and it
should be, nonetheless, noted that current NDDS are still far from optimal with respect to unwanted
release profile being slow or fast and low cellular uptake as a result of pegylation for long blood
circulation, etc.
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Being pioneered in the 1970s, there has always been a growing interest in developing smart
NDDS with the ability to either spatially (at the target site) and/or temporally (at the right time)
release drugs and genes or interaction with biological objects in response to the biological stimuli
(pH, redox potential, reactive oxygen, glucose and specific enzyme) or external triggers (magnetic
field, temperature, light and ultrasound), as cancers exhibit evident variations in these physiological
parameters, rendering them fascinating targets for the design of smart NDDS.
The development of smart NDDS can be a construction process that different functional motifs
with biological sensitivities are built together into formulations using appropriate methodologies.
We next describe the up-to-date strategies of tailoring these stimuli-responsive biomaterials to meet
the current need for nanomedicine advance and clinic translation and their application in controlled
release for the treatment of cancer.

1.4.1 pH
Enlightened by the slightly acidic environment in tumor microenvironment (pH 6.5-7.0), acidic
intracellular compartments with a pH of 5-6.5 in endosomes and a pH of 4.5-5 in lysosomes, a
variety of pH sensitive NDDS have been developed for the controlled release of loaded contents，
with physical or chemical changes of swelling, shrinking, dissociation and degradation. Protonation
of ionizable groups or the degradation of acid labile bonds compose 2 main categories of pH
sensitivity.
One example is the incorporation of tertiary amines in polymethacrylate to precisely target the
acidic endocytic compartments (endosomes and lysosomes). With different pendent tertiary amine
as ionizable groups to impart pH sensitivity, the polymer formed micelles fast and ultra-sensitively
responded to different pH values ranging from 5 to 8 [81]. In light of this, several
isopropylaminoethanol containing drug delivery systems with a pKa of 6.5 were developed for
cancer treatment via phototherapy in combination with chemotherapy [82, 83]. By involvement of
another cationic polymer, pH sensitive NDDS can be achieved for gene therapy [84-86]. Besides,
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the acidic tumor microenvironment was also been exploited for drug delivery development. By the
introduction of 2-(hexamethyleneimino)ethanol to poly(methacrylic acid) (p(HMEMA), the
micelles made from this polymer has a pKa of 6.8~6.9, making them water soluble when
accumulating in tumors, thus exposing the cargo or another component of the micelles. By using
this strategy, endocytosis of siRNA was significantly improved via exposure the siRNA-TCPA
complexes for targeting the overexpressed integrins on HeLa cells [87]. Another two studies
showed that the size change of nanoparticles of 80-90 nm due to fast response of p(HMEMA) to
tumor microenvironment mediated deep tumor penetration of the resulting smaller nanoparticles
(10 nm) for targeting cancer cells and selective release of BLZ-945 in the tumor microenvironment
for depletion of TAM [88, 89].
In addition to ionizable p(HMEMA), the cleavage of amide bonds inside the acidic tumor
microenvironment was also used to site-specifically release the small size prodrug from dendrimer
conjugated platinum prodrug nanoparticles to kill cancer cells in both periphery and center of tumor
[90]. The resulting amine group after hydrolysis in tumor microenvironment can also help increase
the endocytosis of micelles due to its positive charge under philological conditions.

1.4.2 Redox potentials
High redox potential at tumor tissue and cellular level have been widely exploited for
development of NDDS, with the concentration of glutathione (GSH) in the cytosol and nuclei of
cancer cells (0.5-10 mM) are 100-1000 times higher than in body fluid including blood and
extracellular milieu (2-20 µM). It was also reported that the highly hypoxic region within tumors
contains a minimum amount of GSH that is 4-fold higher than normal tissues [91].
The disulfide bonds are cleaved in the presence of GSH, especially at high level. The resulting
thiols can reversely form the disulfide bonds under oxidative conditions. There are a wide variety
of studies that take advantage of this phenomenon to design smart NDDS for intracellular drug
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release. The redox responsive materials that NDDS use are often built in with disulfide bond
containing linkers either between therapeutic agents and polymers or between blocks within
polymer backbone. For example, the insert of a disulfide containing linker between PEG and
polycation segment increased the gene transfection effect because the detachment of PEG reduced
the steric repulsion favoring the entry of cellular polyanions [92]. Some other PEG sheddable drug
delivery systems for cancer treatment were also developed [93, 94]. For drug conjugation, the
incorporation of disulfide containing linker between therapeutic agents and polymer not only solves
the undesirable burst release mostly faced by NDDS in which cargo is physically encapsulated, but
also achieves site specifically drug/gene release, rendering it an appealing strategy for the design
of NDDS [95-100]. Disulfide containing linkers can be used as a cross-linker stabilize nanoparticles
[101-104]. The introduction of the disulfide bonds can be either direct incorporation of small
molecules with disulfide bonds, reduction of cyclic disulfide bonds or thorough oxidation of thiols
by oxidizing agents (O2). In addition to induced collapse of NDDS or controlled drug release by
cleavage of disulfide bond, the consumption of GSH by disulfide bond rich dendrimer can lead to
significant increase of ROS level for fighting cancer [105]. Recently, researchers found cell
penetration poly(disulfides) could assist the intercellular delivery of NDDS with rapid cellular
uptake, minimal cytotoxicity and efficient degradation by GSH [106].
In addition, Au-S bond constitutes another category of chemical bonds that respond to GSH. It
is stable under physiological conditions, but bond forming thiol atom can be replaced by free thiols,
In a study, drugs with thiol group were conjugated to PAMAM encapsulated gold nanoparticles via
Au-S bond and released by the treatment of GSH [107].
The overproduction of ROS is another typical disease hallmark in tumor tissue and tumor cells
[108-110]. ROS, including superoxide, hydroxyl radical, hypochlorite ion, hydrogen peroxide,
singlet oxygen, etc., are often produced in mitochondria, endoplasmic reticulum (ER) and plasma
membrane by NADPH oxidase. The generated ROS participates in multiple biological processes,
such as the regulation of proteins and cell signaling, hormone synthesis, cell proliferation and
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inflammation mediation. However, the overproduction of ROS can cause the oxidation of proteins
and mutation of DNA, thus often accompanying the development of tumor. As a result, the
abundant ROS can be treated as a target of tumor or a marker that is distinct from its surrounding
normal tissues. This abnormality in tumors inspired researchers to design the site selective NDDS
based on this unbalanced ROS levels.
Similar to the development of redox responsive NDDS by incorporation of disulfide bonds and
Au-S bond, etc., the sensitivity of NDDS to ROS can be conferred by the introduction of
arylboronic acids, thioketal, thioether, proline esters and some other chemical bonds [111, 112].
For example, a polyprodrug was successfully synthesized through thioketal linkage. Upon
oxidation by oxidants, polyprodrug in NDDS was degraded and released the relevant parent drug,
causing tumor regression [113]. A polymer consisting of polypeptide with pendant arylboronic
acids exhibited high drug loading capability for alkyl amine containing drugs and rapidly released
the encapsulated DOX at oxidative environment [114]. Furthermore, a variety of ROS responsive
gene and/or drug NDDS with arylboronic aids and quaternary amines were developed to treat
cancer [115, 116].
Diselenide linkage is another attractive and special motif to be used in the development of smart
NDDS, in which diselenide bonds not only react to reductants but also exhibit high sensitivity to
oxidants. Compared to disulfide bond, diselenide bond is more sensitive to redox cleavage due to
its lower bond energy (172 kJ/mol vs 268 kJ/mol). Thus, similar approaches used in the design of
redox responsive NDDS with disulfide bonds can also be applied in gene therapy and chemotherapy
[117]. In a recent study, camptothecin (CPT) and doxorubicin (DOX) were released from the
nanoparticle in a controlled manner with the reduction of diselenide bond in cross-linker in tumor’s
redox microenvironment [118]. NDDS with sheddable PEGs linked by diselenide linkage was also
constructed to controlled docetaxel (DTX) release [119].
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In addition, the diselenide bonds insides NDDS exhibit high sensitivity to oxidants. By treating
cross-linked micelles with diselenide bonds containing linkers to tumor mice, the micelles
dissembled and released the encapsulated DOX upon the cleavage of diselenide bonds in ROS
abundant tumor regions, resulting in suppression of tumor growth [120].

1.4.3 Enzymes
Given the important role of enzymes in various biological process, targeting the enzyme
dysregulation has attracted considerable attention in the development of NDDS. For example, ester
bonds are often constructed into delivery systems because they subject to enzymatic digestion while
are relatively stable under philological conditions. By targeting abundant esterase in tumor cells,
charge reversal gene delivery systems were developed, resulting from generation of the pendent
negatively charged carboxylic acids after the cleavage of ester bonds [121, 122]. In addition,
azobenzene linkers are also exploited by researcher for controlled drug release by oxidoreductase
enzymes in the hypoxic tumor environment [123].
MMPs are the enzymes that are overexpressed within tumors and responsible for various tumor
processes and hydrolysis of specific amide bonds. A number of NDDS that respond to MMPs were
developed, generally with built-in MMP cleavable structures in materials capable of loading and
releasing cargos to perform their function. Sizes of NDDS affect the tumor penetration [124, 125].
Being degraded by MMPs after accumulation of multistage quantum dot (QD)-covered gelatin
nanoparticles in tumor, quantum dots (QD) (10 nm) was released from gelatin matrix, leading to
enhancement of tumor penetration. Although a bunch of natural MMP degradable compounds are
available such as collagen, gelatin and fibrinogen, their application in drug delivery are limited due
to the big size. Synthetic short-sequence peptides emerge as potential candidates as a result of their
small size [126]. As discussed above, prolonging blood circulation time of NDDS by pegylation
brings a cost of reduced cellular uptake due to poor interaction between tumor cells and NDDS. A
design for polymeric NDDS that utilized the MMP-sensitive linker inserted between PEG and
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hydrophobic blocks served the purpose to increase the cellular uptake of related NDDS. Upon
accumulation in tumors, de-pegylation occurred on account of the cleavage of MMP-sensitive
linkers by the ubiquitous MMPs, contributing to a subsequent improved cellular uptake [127, 128].
Cathepsins are another class of overexpressed lysosomal cysteine proteases in tumors [129]. To
target the tumors, drugs are generally conjugated to polymers (including HPMA, PEGylated
dendrimer) with a short peptide linker (GFLG) to avoid burst release and selectively release upon
uptake by cathepsin-ample cancer cells [130, 131].

1.4.4 Temperature
Amphiphilic polymers that exhibit temperature sensitivity with a lower critical solution
temperature (LCST) constitute one of the categories for the development of smart NDDS. These
polymers are solubilized in aqueous solution when the environmental temperature is below their
LCST but undergo abrupt phase transition that hydrophobically collapse and aggregates at
temperature higher than their LCST, or vice versa. By sophistically tuning the LCST of polymers
to be greater than the body temperature and lower than the temperature of heated tumors (T ≈ 42
o

C), thermal targeting of tumors can be achieved [132].
One of the most used temperature sensitive polymers is poly(N-isopropylacrylamide)

(PNIPAAm), with an adjustable LCST ranging from 32 oC to even higher than 45 oC by
incorporation of hydrophobic motifs. Its application in drug delivery was first proposed in the 1980s
[133, 134]. The thermo-sensitivity of PNIPAAm was utilized as a gate for controlled release by
inorganic nanotubes, with drug release at temperature > LCST due to sol-to-gel phase transition of
PNIPAAm [135]. The usage of single wall nanotubes (SWNT and PNIPAAm to treat gastric cancer
reported by another study worked the same way that drug was released after PNIPAAm
transformed to coil structure at 37oC due to the surface exposure of SWNT which was immersed
in PNIPAAm solution at T < 37oC [136].
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Elastin-like polypeptides (ELPs) are another widely used polymer system that comprise a
pentapeptide sequence (VPGXG)n [132]. In contrast to full synthetic PNIPAAm, these
biodegradable polymers are genetically encodable, allowing more precise control over the sequence,
chain length and the number of repeated monomers in contrast to PNIPAAm. Thermal targeting
was achieved by taking advantage of thermally sensitive ELPs, with more accumulation of ELPdrug conjugates in tumor compared to ELPs that do not go through phase transition [137]. Besides,
an ELP depot of radiotherapeutics were formed within tumor via coacervation at temperature above
its LCST, successfully delayed the tumor growth [138, 139].

1.4.5 Hypoxia
Hypoxia is closely associating with tumor progression and therapy resistance and fascinates
researchers to engineer biomaterials for the development of hypoxia responsive NDDS.
Enlightened by rapid conversion of nitroaromatic derivatives to hydrophilic 2-aminoimidazoles
under hypoxia condition, this motif is exploited to construct hypoxia responsive NDDS for
treatment of cancer: original hypoxia of tumor induced NDDS disassembly and fast release of
hypoxia activated drug and initiated phototherapy caused by change of solubility in polymer due
to the aforementioned conversion; the hypoxia of tumors was exacerbated by phototherapy, further
accelerating the first step; cancer cells were killed by chemodrugs and produced 1O [140]. The
introduction of azobenzene between PEG and PEI also increased efficiency of siRNA delivery,
resulting from the cleavage of azobenzene under hypoxia conditions [141].

1.5 Significance of Current Study
Current study will focus on the treatment of pancreatic cancer and chemo-resistant cancer.
Gene delivery systems often cause severe systemic toxicity and fast clearance by RES due to high
positive charge of delivery materials [142]. Hydrophobic interaction for drug loading is not always
applying to every drug. For example, rubone that we used in the second project is a highly
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hydrophobic drug which had a relatively low drug loading in lipid polymer that generally
incorporate drugs through hydrophobic interactions. Benefiting from rapid advances in the material
science [67, 143], we successfully synthesized two polymers that is either responsive to abundant
ROS within tumors or acidic microenvironment and high levels of intracellular GSH for controlled
drug release.
In the first work for treatment of pancreatic cancer, arylboronic acid was incorporated into the
cationic polymer with quaternary amines. This polymeric delivery system exhibited high drug
loading capacity for amine containing drugs through donor receptor interaction and showed good
complexation with miR-34a. The simultaneously solve the co-delivery for small molecule drugs
and genes without causing unwanted severe systemic toxicity that generally faced by lots of other
gene delivery systems, such as PEIs.
In the second work, we aimed to treat taxane-resistant prostate cancer resulted from populated
CSCs. To suppress the tumor growth, rubone was used to kill chemo-resistant CSCs and DTX was
used to kill the bulk tumor cells. Given the difficulty in loading rubone, we used conjugation
strategy to addresses low loading of rubone. By incorporation of a disulfide containing linker
between rubone and the polymer, GSH responsive drug release was achieved. The pendent
ionizable isopropylaminoethyl groups confer the polycarbonate with pH sensitivity. When
endocytosed into acidic endocytic compartments by cancer cells, the micelles were capable of
rapidly releasing the encapsulated DTX and conjugated rubone, maximizing the potential of tumor
treatment by overcoming the notorious chemoresistance and minimizing the possibility of induced
chemo-resistance due to slow drug release.
By taking advantage of chemotherapy as well as gene therapy, current study successfully
inhibited the tumor growth by using stimuli responsive NDDS.
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Chapter II
ROS responsive polymeric micelles for
triggered simultaneous delivery of PLK1
inhibitor/miR-34a and effective
synergistic therapy in pancreatic cancer
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2.1 Abstract
Ineffective drug delivery and poor prognosis are two major challenges in the treatment of
pancreatic ductal adenocarcinoma (PDAC). While there is significant downregulation of tumor
suppressor microRNA-34a (miR-34a), which targets many oncogenes related to proliferation,
apoptosis and invasion, high expression level of Polo-like kinase 1 (PLK1) is closely associated
with short survival rates of pancreatic cancer patients. Therefore, the objective is to co-deliver miR34a mimic and small molecule PLK1 inhibitor volasertib (BI6727) using poly (ethylene glycol)poly[aspartamidoethyl (p-boronobenzyl) diethyl ammonium bromide] (PEG-B-PAEBEA) This
polymer could self-assemble into micelles of ~100 nm with 10 % drug loading of volasertib and
form complex with miR-34a at the N/P ratio of 18 and higher. Combination treatment of volasertib
and miR-34a displays synergistic effect and superior anti-proliferative activity along with an
enhanced G2/M phase arrest and suppression of colony formation, leading to cell death due to
potential c-myc targeting therapeutics. Orthotopic pancreatic tumor bearing NSG mice are scanned
for fluorescence by IVIS after systemic administration of micelles encapsulating volasertib and
miR-34a at doses of 5 mg/kg and 1 mg/kg, respectively. Cy5.5 concentration in plasma and major
organs is determined by measuring fluorescence intensity. A significant reduction in tumor volume
was observed in pharmacodynamic study with negligible systemic toxicity proved by histological
evaluation. In conclusion, PEG-B-PAEBEA micelles carrying volasertib and miR-34a mimic
provide strong potential on pancreatic cancer treatment by improving drug delivery behaviors.

2.2 Introduction
Pancreatic ductal adenocarcinomas (PDAC) is one of the most aggressive cancers, where 85%
of patients have metastatic disease making surgical interventions ineffective. High mortality of
pancreatic cancer patients are due to late-stage prognosis and development of chemoresistance
upon prolonged treatment with chemotherapeutic drug(s) [1]. Gemcitabine is the first line Food
and Drug Administration (FDA) approved drug used alone or in combination with others to
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improve the quality and lifespan of PDAC patient [2]. However, pancreatic tumors present a
complex and highly obstructive microenvironment that is characterized by dysregulation of
miRNAs and development of chemoresistance [3]. Alteration of miRNA expression and
replenishment of anticancer miRNAs may effectively restore chemosensitivity by decreasing the
expression of essential genes involved in cell growth or survival [4]. Meanwhile, polo-like kinase
1 (PLK1) emerges as a promising target due to the mediation of gemcitabine resistance and
regulation of mitosis [5, 6].
MicroRNAs (miRNAs) are 17-25 nucleotides long and highly conserved and non-coding RNA
products, play critical roles in the regulation of drug resistance, cancer stem cell (CSC) proliferation
and cancer metabolism [7, 8]. The advantage of miRNAs lies in their ability to modulate multiple
cellular pathways simultaneously, which is difficult to be accomplished using small molecules and
therapeutic proteins [9]. Cellular stimuli, glucose level, and hypoxia critically orchestrate miRNA
activity in various pathologies, including pancreatic cancer [10]. Among many miRNAs, miR-34a
is downregulated in PDAC patients and has a key role in chemosensitization [11]. Increase in miR34a expression level contributes to the suppression of Bcl-2, a well-known anti-apoptotic gene,
leading to decrease in migration, invasion and proliferation, and enhancement in apoptosis of tumor
cells [12, 13], thereby overcome drug resistance and treat PDAC more efficiently.
Polo-like kinase 1 (PLK1) plays a key role in mitosis and meiosis, and its overexpression has
been found in various cancer types, including pancreatic cancer. Moreover, higher PLK1
expression correlates with tumor aggressiveness and a poor prognosis. Therefore, PLK1 is an
attractive target for treating pancreatic cancer. Recently, several PLK1 inhibitors, including
volasertib and GSK461364, have been investigated in various cancers. Volasertib is an ATPcompetitive kinase inhibitor with higher potency and selectivity than those of its predecessor, BI
2536. Treatment with volasertib[14] results in the inhibition of G2/M cell cycle arrest in cancer
cells [15, 16]. Most importantly, combination treatment with Bcl-2 and PLK1 inhibitors specifically
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induces synergistic cell death due to the depletion of c-myc, a common target miR-34a and PLK1
[17]. Here, we hypothesized that combination of miR-34a and volasertib could synergistically and
effectively treat PDAC.
Considering the challenges that miRNAs and hydrophobic drugs face, including off-target
effects, low transfection efficiency, poor aqueous solubility and burst release, recent efforts have
been focused on developing nanocarriers for delivery of both of miRNAs and hydrophobic drugs
[18]. Compared with conventional drug delivery systems which have poor bioavailability, adverse
side effects and low therapeutic indices [19], polymeric nanoparticle delivery systems have
generated considerable commercial and translational attention due to their potential for extended
drug release kinetics and enhanced stability [20]. Cationic polymers and lipids are widely used for
miRNA delivery [21, 22]. Unfortunately, the highly positive charge systems with high density of
amines will generate severe and intense toxicity, impeding their clinical translation.
We previously reported methoxy poly(ethylene glycol)-block-poly(2-methyl-2-carboxylpropylene carbonate-graft-dodecanol-graft-tetraethylene pentamine) (mPEG-b-PCC-g-DC-gTEPA) conjugated polycarbonate-based polymer for co-delivery of miRNA and small molecules
with high drug loading and efficient complex formation with miRNA for treating type I diabetes
and pancreatic cancer [23-25]. However, the polymer synthesis requires multiple steps, and
polycarbonate is subjected to degradation when being modified under alkali condition. Nonspecific hydrophobic interactions between the drug and polymer often lead to drug aggregation and
decrease in drug-loading [26]. Moreover, the intracellular dissociation and release of miRNAs and
drugs from delivery systems is well-known to be the prerequisite for effective transfection and
therapy, whereas miRNA/polymer complexes are thermodynamically unstable and the drugpolymer conjugates linked with chemical bonds are even more resistant to release cargos under
physiological environment. Therefore, it is highly desirable to develop a nanocarrier that can not
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Figure 2.1 Illustration of combination therapy of small molecule PLK1 inhibitor and microRNA34a in pancreatic cancer.

only co-load both gene and drugs, but also effectively dissociate and rapidly release the cargos in
cancer cells. To date, low pH in acidic endocytic vesicles and increased level of glutathione (GSH)
as well as oxidative species in cancer cells have encouraged the development of polymers which
are sensitive to specific stimuli for bio-imaging and cancer treatment [27]. Inspired by these recent
advances, we hypothesize the overproduced reactive oxygen species (ROS) can be exploited as a
cancer related stimulus to mediate successfully cargo release from nanocarriers in the cytoplasm
[28]. Taken together, we present a synthetic polymeric delivery system of miR-34a and volasertib
for treating pancreatic cancer. We synthesized poly(ethylene glycol)-poly[aspartamidoethyl(pboronobenzyl)diethyl ammonium bromide] (PEG-B-PAEBEA), which could form stable micelles
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in aqueous solution with both of miR-34a and volasertib through electrostatic interaction of nucleic
acid and quaternary ammonium and intense nitrogen-boron (N-B) coordination of tertiary amines
and boronic acid, respectively. Upon oxidation by ROS, boronic acid would be first detached,
followed by a self-immolative process to produce tertiary amines and para-quinone methide,
leading to rapid release of miR-34a and volasertib, thereby improving the potential of their
antitumor effects and minimal systemic toxicity (Figure 2.1). In this study, the biodistribution,
therapeutic efficacy and systemic toxicity of miR-34a and volasertib loaded micelles was measured
on orthotopic pancreatic tumor-bearing NSG mice by intravenous injection.

2.3 Experimental section
2.3.1 Materials
Dulbecco's Modified Eagle Medium (DMEM) high glucose medium, Dulbecco’s
phosphate buffered saline (DPBS) and 0.25% trypsin were purchased from Hyclone (Logan, UT).
Keratinocyte-SFM medium, bovine pituitary extract, and human recombinant EGF were purchased
from Gibco (Chevy Chase, MD). Heat inactivated fetal bovine serum (FBS), antibiotic-antimycotic
for cell culture, RIPA buffer for cell lysis, hlatTM protease and phosphatase inhibitor cocktail (100×),
PierceTM BCA protein assay kit, H2DCFDA (D399) and FxCycleTM PI/RNase staining solution
(F10797) were purchased from Thermo Fisher Scientific (Waltham, MA). HEPES buffer was
purchased from Millipore Sigma (St. Louis, MO). Human PLK1 primary antibody was purchased
from cell signaling technology (Danvers, MA). Human c-myc primary antibody was purchased
from Proteintech (Manchester, UK). β-actin primary antibody was purchased from Santa Cruz
Biotechnology (Dallas, TX). Dithiothreitol (DTT), 4×Laemmli buffer, 10×Tris/Glycine/SDS
protein electrophoresis running buffer (pH 8.3) and 10×TBS buffer were purchased from Bio-Rad
(Hercules, CA). Volasertib was purchased from Adooq Bioscience (Irvine, CA). miR-34a was
purchased from GE Healthcare Dharmacon, Inc. (Lafayette, CO).
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2.3.2 Synthesis of poly(ethylene glycol)-poly[aspartamidoethyl(p-boronic acid) benzyldiethyl
ammonium bromide] (PEG-B-PAEBEA)
Step 1. Triphosgene (2.744 g, 9.24 mmol) dissolved in 10 mL of tetrahydrofuran (THF) was added
to a suspension of benzyl aspartate (4.7 g, 21 mmol) in 200 mL of THF with stirring and the mixture
was then heated to 50 °C. Once the suspension became clear (approximately 30 min). Then, the
solvent was removed under reduced pressure. The resultant solid was recrystallized from excess
hexane. Finally, 4.459 g of β-benzyl-L-aspartate N-carboxy anhydride (BLA-NCA) was obtained
with a yield of 85%. 1H NMR (500 MHz, CDCl3, δ): 7.43 – 7.15 (m, 5H), 5.13 (s, 2H), 4.69 (t, J =
4.5 Hz, 1H), 2.98 (ddd, J = 88.8, 17.8, 4.5 Hz, 2H).
Step 2. A solution of BLA-NCA (2.739 g, 11 mmol) in N,N-dimethylformamide (DMF) was added
to a stirred solution of mPEG-NH2 (1.0 g, 0.2 mmol) in DMF under N2 atmosphere. The solution
was heated to 40 °C and kept stirring for 72h. The resulting mixture was poured to a large amount
of diethyl ether. The resulting solid was collected by filtration and dried to afford poly(ethylene
glycol)-poly(beta-benzyl-L-aspartate) (PEG-PBLA) copolymer (2.99 g, 80%).
Step 3. PEG-PBLA (2 g) was first dissolved in DMF, followed by the addition of N, Ndiethylethylene diamine (4 equivalent to BLA unit) and triethylamine (TEA) (4 equivalent to BLA
unit). The mixture was stirred at 35 °C overnight. Afterwards, the mixture was dialyzed against
distilled water and lyophilized to produce poly(ethylene glycol)-poly(beta-diisoethylamino-ethylaspartamide) (PEG-PAsp(DIE)), with a yield of 77%.
Step 4. In a 50 mL round bottom flask, (4-(bromomethyl)phenyl boronic acid (2.5 equivalent of
DIE unit) and PEG-Pasp(DIE) (700 mg) were dissolved in DMF and stirred at 50 °C for 24h. Then,
the resulting mixture was dialyzed against deionized water and the final product poly(ethylene
glycol)-poly[aspartamidoethyl(para-boronic acid ) benzyl diethyl ammonium bromide] (PEG-BPAEBEA) was obtained as white solid after lyophilization, with a yield of 69%. The chemical
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structure of PEG-B-PAEBEA was determined by 1H NMR and its molecular weight and
polydispersity (PDI) were determined by gel permeation chromatography (GPC) under following
conditions: Styragel® HR 4E column (5 µm, 7.8×300 mm) at 40 °C and flow rate of 1 mL/min.
DMF (containing 1 % lithium bromide) was used as the mobile phase and injection volume is 20
µL.

2.3.3 Cell culture
MIA PaCa-2 and Capan-1 cell lines were purchased from American Type Culture Collection
(ATCC, Manassas, VA), MIA PaCa-2 resistant (MIA PaCa-2R) and Capan-1 resistant (Capan-1R)
cells were generated from MIA PaCa-2 and Capan-1 by incubating with gemcitabine (GEM),
respectively. All the above cell lines were maintained in high glucose DMEM medium
supplemented except human pancreatic duct epithelial (HPDE) cells with 10% FBS and 1%
penicillin/streptomycin at 37 °C, 5% CO2 and 100% humidity, and were split when confluent.
HPDE cells were cultured in Keratinocyte-SFM supplemented bovine pituitary extract (BPE) and
human recombinant EGF in the identical atmosphere.

2.3.4 Preparation and characterization of nanoparticles
Volasertib (1 mg/mL) dissolved in acetone (100 µL) was added drop by drop to acetone solution
of the copolymer (1 mg) under stirring at the room temperature. To remove the residual acetone,
the samples were evaporated under reduced pressure. These nanoparticles were then used for
complex formation with miR-34a or scrambled miRNA by mixing at an equal volume and
vortexing gently for 30s followed by incubation at room temperature for 30 min. Rhodamine (Rho)
labeled nanoparticles were prepared by dissolving Rho and volasertib in acetone, which was then
mixed with the polymer solution under stirring. FITC labeled nanoparticles were fabricated by
forming complex between FITC-labeled miRNA and nanoparticles. Particle size distribution and ζ
potential were determined by dynamic light scattering (DLS) using a Malvern Zetasizer
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(Worcestershire, UK) at 25 °C. Surface morphology of these nanoparticles was determined by
transmission electron microscopy (TEM, Burlington, NC). The encapsulation efficiency (EE) and
drug loading (DL) of volasertib were calculated using the following formulas:
EE (%) = Amount of volasertib encapsulated/Amount of volasertib added × 100% (1)
DL (%) = Amount of volasertib encapsulated/Amount of polymer × 100% (2)

2.3.5 miRNA binding ability
The miRNA complexation efficiency was assessed by agarose gel retardation assay.
Nanoparticles were prepared at various N/P ratios, and miRNA was used as a control. 20 µL of
nanoparticles were mixed with 6 µL of 6×loading buffer, and then the mixture was loaded onto 0.8%
(w/v) agarose gel containing 0.5 µg/mL of ethidium bromide (EB). Electrophoresis was performed
at a constant voltage of 110 V for 20 min in 1×TBE running buffer. The migration of miRNA bands
was visualized and photographed with a using GelDoc Ez system (Bio-Rad, Hercules, CA).

2.3.6 ROS-triggered degradation of PEG-B-PAEBEA and release of miRNA
PEG-B-PAEBEA (5 mg) was dissolved in D2O (1 mL) with 15 mM H2O2 solution at 37 °C. At
given time points (1 h and 24 h), the solution was detected by 1H NMR. To confirm the ROS
responsiveness release of miRNA, nanoparticles at mass ratio of 32 were incubated with final H2O2
concentrations at 0.25, 0.5, 0.75 and 1.5 mM, respectively. Those solutions were then subjected to
the electrophoresis as descried above after incubation for 1 h at 37 °C. Naked miRNA were used
as a control.

2.3.7 Critical micelle concentration (CMC)
Critical micelle concentration (CMC) was determined with fluorescent spectroscopy using
pyrene as a hydrophobic fluorescent probe [27]. Briefly, 1 mL of micelle samples were prepared in
DI water with concentration ranges from 1×10-7 to 0.5 mg/mL and pyrene stock solution (1.2×10-6
M) was added to micelle samples. The emission fluorescent intensity of 384 nm and 373 nm was
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recorded with an excitation wavelength of 334 nm. The intensity ratio (I384/I373) was plotted
against the logarithm of micelle concentrations.

2.3.8 Fluorescence resonance energy transfer
For fluorescence resonance energy transfer (FRET) determination, FITC and Rhodamine were
employed as the donor and acceptor, respectively. The dual-labeled nanoparticles carrying FITC
labeled miR-34a and volasertib were fabricated by using Rho-labeled polymer. The emission
spectra of FITC-miRNA and dual-labeled nanoparticles from 500–700 nm were scanned at an
excitation wavelength of 490 nm (donor) using a fluorescence spectrometer.

2.3.9 Measurement of ROS production
ROS produced by cells were detected using 2’,7’-dichlorofluorescin diacetate (DCFDA), which
can passively diffuse across cell membranes. DCFDA is deacetylated by esterases to
dichlorofluorescein (DCFH) and subsequently reacts with ROS to generate the green fluorophore,
DCF [52]. MIA PaCa-2R cells were seeded in 12 well plates for 24 h, incubated with free volasertib
and nanoparticles carrying ether miR-34a, volasertib or their combination. The concentration of
volasertib and miR-34a were fixed at 50 and 100 nM. After 24 h, cells were removed from growth
media, resuspended in pre-warmed PBS containing 5µM DCFDA and incubated 30 min at 37°C.
Then the cells were washed with PBS for three times and resuspended in serum-free media.
Fluorescence was respectively measured by flow cytometry (Becton, Dickinson, NJ) with
excitation at 490 nm and emission at 520 nm.

2.3.10 Cytotoxicity, synergistic effect and apoptosis
Cytotoxicity of volasertib, miR-34a, and their combination was determined by MTT assay.
MIA PaCa-2, MIA PaCa-2R, Capan-1 and Capan-1R cells were plated at a density of 5,000
cells/well in a 96-well plate for 24 h incubation. Then, free volasertib and formulations containing
volasertib, or the combination of volasertib and miR-34a were added to 96-well plates with
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volasertib concentration ranging from 10 to 1000 nM and miR-34a concentration from 10 to 200
nM, respectively. After 48 h of incubation, 5 mg/mL MTT solution was added and cells were
cultured for another 3 h. The supernatant was discarded and 200 µL DMSO was added to each well.
Cell viability was determined by a Spectrophotometer. The combination index (CI) and dose
reduced index (DRI) were calculated using CompuSyn 1.0 software (ComboSyn, Inc., USA). In
addition, CI <1, CI = 1 and CI > 1 indicated synergistic, additive and antagonistic effects,
respectively. To demonstrate ROS-responsive cytotoxicity, cells were treated with dithiothreitol
(DTT, 5mM), a potent ROS scavenger, for 6 h prior to incubation with formulations.
For apoptosis assay, MIA PaCa-2R cells were seeded in 12 well plates for 24 h, incubated with
nanoparticles carrying ether miR-34a, volasertib or their combination. We also used scrambled
miRNA complexed nanoparticles as well as free volasertib as controls. Volasertib and miR-34a
were fixed at 50 and 100 nM concentrations, respectively. These cells were incubated for 24 h,
washed with PBS for three times, and stained with Annexin V-Cy5/PI apoptosis kit according to
the manufacturer’s protocol. The early and late apoptosis rates were calculated by flow cytometry
(Becton, Dickinson, NJ).

2.3.11 Colony formation assay
MIA PaCa-2R cells were transfected with volasertib, miR-34a, and their combination for 24 h
using scrambled miRNA as control. Transfected cells were reseeded in the 12-well plate at 1000
cells per well. Cells were cultured for 14 days, then plates were washed with PBS, fixed with
formalin, stained with 5% crystal violet for 30 min, washed with tapping water and photographed.

2.3.12 Cell cycle
2×105 MIA PaCa-2R cells were seeded in a 6-well plate for 24 h and incubated with volasertib,
miR-34a, and their combination, respectively using scrambled miRNA as a negative control. After
48 h, cells were harvested through trypsinization, fixed by 70 % ethanol, washed three times by
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PBS, centrifuged and then the supernatant was decanted, leaving a pellet of cells in each sample
tube. Then, 0.5 mL of FxCycleTM PI/RNase staining solution was added to each sample tube and
incubated for 15 min at room temperature while protecting from light. Finally, flow cytometry was
utilized to analyze the samples using excitation at 532 nm and emission at 585 nm.

2.3.13 3D spheroid tumor model
MIA PaCa-2R cells (4 × 103 cells in 40 μL per well) in DMEM medium with 10 % FBS were
seeded onto Perfecta3D® 96-Well Hanging Drop Plates (3D Biomatrix, Inc., Ann Arbor MI) in
triplicate and incubated at 37 °C, 5% CO2. On 4th day, the spheroids were then treated with
nanoparticles carrying either miR-34a, volasertib or their combination. Cells treated with PBS,
scrambled miRNA and free volasertib were used as controls. Morphologies of tumor spheroids
were visualized under a microscope on day 2, 4 and 6 to check the cytotoxic efficacy of different
formulations.

2.3.14 Cell migration in vitro
Inhibition of cell migration was evaluated by scratch wound healing assay and Transwell® assay,
respectively. For scratch wound healing assay, MIA PaCa-2R cells (2 × 105 per well) were plated
onto a 12-well plate. Then, cells were treated with nanoparticles carrying either miR-34a, volasertib
or their combination. Cells treated with PBS, scrambled miRNA and free volasertib were used as
controls. At 24h post treatment, a wound was created in each well using 200 µL tips, dislodged
cells were washed with PBS and treatment were re-added for 24 h and 48 h, respectively. Cell
migration assay was performed using Transwell® chambers in MIA PaCa-2R cell lines. MIA PaCa2R cells were cultured at a density of 4 × 105 cells/well in 6-well plates for 24 h prior to use. The
cells were treated with nanoparticles carrying miR-34a, volasertib or their combination. Cells
treated with PBS, scrambled miRNA and free volasertib were used as controls. These formulations
were incubated in 2 mL of culture media without serum for 6 h, followed by two washes with PBS
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and incubation in DMEM medium with 10% FBS for an additional 24 h. The cells were harvested
and 200 µL of cell suspension in DMEM medium was added into the upper chamber of Transwell®.
Subsequently, 1 mL of DMEM with 20 % FBS as the chemoattractant was added into the lower
Transwell® chamber and the cells were incubated for 24 h. Then, cells that did not migrate through
the pores were carefully removed using a cotton-tipped swab. The filters were fixed in 4%
paraformaldehyde, dried in room temperature, and stained with crystal violet.

2.3.15 Real time RT-PCR
HPDE, MIA PaCa-2, MIA PaCa-2R, Capan-1 and Capan-1R cells were cultured in 6-well
plates at a density of 2×105 cells/well for 24 h, transfected with volasertib or miR-34a for 24 h.
Cells were then subjected to extraction of total RNA using RNAeasy isolation kit (Qiagen, Valencia,
CA). Reverse transcription reaction of total RNA to cDNA was carried out using miScript ІІ
Reverse Transcription kit and Taqman® Reverse Transcription reagents (Thermo Fisher, Waltham,
MA), respectively. miR-34a and PLK1 mRNA levels and c-myc were quantitatively assayed in a
real-time PCR system (Roche, Basel, Switzerland) using miScript SYBR Green dye universal
master mix, miR-34a primer as well as primers of PLK1 and c-myc on a Light Cycler 480 (Roche,
Indianapolis). U6 was used as a housekeeping gene and relative amount of miR-34a, PLK1 and cmyc was calculated using the crossing point (Cp) value. Primers were designed as: PLK1 FWD:
5’-CAGCAAGTGGGTGGACTATT-3’, PLK1 REV: 5’- ATCAGTGGGCACAAGATGAG-3’; cmyc

FWD:

5’-CACGAAACTTTGCCCATAGC-3’,

c-myc

REV:

5’-

GCAAGGAGAGCCTTTCAGAG-3’.

2.3.16 Western blot analysis
MIA PaCa-2 and MIA PaCa-2R cells in 6-well plates with a density of 2×105 cells/well were
incubated with formulations for 24 h, followed by protein isolation with radioimmunoprecipitation
assay (RIPA) buffer and determination with a BCA protein assay kit. The cell lysates were then
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mixed with loading buffer, boiled buffer at 100 °C for 5 min, loaded on the wells of SDS-PAGE
gel, transferred by electroporation to polyvinylidene difluoride (PVDF) membrane, incubated with
blocking buffer for 1 h at room temperature, cultured with PLK1, Bcl-2 and c-myc rabbit primary
antibodies as well as β-actin primary antibody overnight at 4°C and IR fluorescent dye labeled
secondary antibodies was added, followed by analysis using Licor Odyssey system (LI-COR
Biotechnology, Lincoln, NE). β-actin was used as the loading control.

2.3.17 Biodistribution and therapeutic studies
All the animal experiments were approved by the Institutional Animal Care and Use Committee
(IACUC) of the University of Nebraska Medical Center, Omaha, USA and carried out as per the
National Institutes of Health (NIH) use guidelines. The orthotopic human pancreatic cancer mouse
model was developed using 6-8 week male NSG mice (24-30 g). Luciferase stably expressing MIA
PaCa-2R cells (1×106) were mixed with Matrigel (2:1) using ice-cold instruments and syringes.
Then mice were anesthetized using isoflurane in an induction chamber, and 20 µL of Matrigel-cell
suspension was orthotopically injected into the pancreas tail. Tumor growth was monitored using
an IVIS Spectrum In Vivo Imaging System (PerkinElmer, Hopkinton, MA) after intraperitoneal
administration of 20mg/mL luciferin to mice (150µL per mouse). Three weeks after tumor injection,
free Cy5.5 and Cy5.5 labeled micelles were injected to mice via the tail vein at a single of Cy5.5 at
the dose of 0.1 mg/kg. To localize Cy5.5 labeled micelles, the mice were observed in the IVIS
imaging system at an excitation wavelength of 640 nm and emission wavelength of 710 nm at 1, 2,
4, 8, 24 h. After in vivo imaging, mice were sacrificed and major organs such as tumor, heart, liver,
spleen, lung and kidney were collected for ex vivo imaging.
For therapeutic study, mice were randomly divided into 5 groups (n=5 per group) when the
bioluminescence reached 1×106. Formulations including were administered via tail vein with
volasertib 5 mg/kg and miR-34a 1 mg/kg every three days in a total of 7 injections, according to
the animal’s weight. Body weights were measured every time before injection. At the 3rd day after
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the 7th administration, the animals were euthanized to harvest major organs such as tumor, heart,
liver, spleen, lung and kidney haematoxylin and eosin (H&E) staining, immunohistochemical and
Western blot (WB) analysis.

2.3.18 Statistical analysis
Results are presented as the mean ± standard deviation (SD). One-way analysis of variance
(ANOVA) was carried out to assess the statistical significance of the differences between groups.
P < 0.05 indicated significant differences.

Figure 2.2 Synthesis and characterization of PEG-B-PAEBEA. (A) Synthesis scheme for PEGB-PAEBEA. (B)1H NMR spectrum of PEG-B-PAEBEA in TFA-d6. (C) Molecular weight of
PEG-PBLA confirmed by GPC.
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2.4 Results
2.4.1 Copolymer synthesis and characterization
A reactive oxygen species (ROS)-labile charge-reversal polymer PEG-B-PAEBEA was
synthesized by a 4-step process and characterized by 1H NMR. Briefly, BLA-NCA was produced
from the reaction of L-aspartic acid β-benzyl ether, followed by copolymerization with mPEG-NH2
(Mw=5000) to produce PEG-PBLA. Afterwards, N, N-diethylethylenediamine (DEEDA) replaced
the benzyl groups through aminolysis, affording PEG-PAsp(DIE). Finally, the reaction between 4(bromomethyl)phenyl boronic acid and PEG-PAsp(DIE) gave the final product PEG-B-PAEBEA
(Figure 2.2 A-B). The molecular weight of PEG-PBLA was 12,594 Da with PDI of 1.04 according
to GPC determination (Figure 2.2 C). PEG-B-PAEBEA had strong interactions with the GPC
column due to the positive charge, so their molecular weight could not be measured by the GPC
and were calculated from their precursor PEG-PBLA. According to the 1H NMR spectrum of PEGB-PAEBEA in Figure 2.2 B, 15 4-methylphenyl boronic acids were attached to tertiary amines of
PEG-PAsp(AIE), as based on the integrated areas of the peak at 5.28 ppm (assigned to methylene
hydrogens of -PEG). Thus, the molecular weight of PEG-B-PAEBA is 14,611 Da.

2.4.2 Preparation and characterization of micelles
Volasertib loaded micelles were prepared by precipitation using PEG-B-PAEBEA and coating
drug particles through N-B coordination, thereby allowing the micelles to achieve a positively
charged surface for complex formation with miR-34a via ionic interaction. The mean particle size
of micelles was 90.1 ± 0.3 nm with volasertib loading of 10.8 ± 0.1 %, volasertib encapsulation
efficiency of 96.7 ± 0.8 %, and ζ potential of 35.5 ± 2.7 mV (Figure 2.3 A). The polymer effectively
condensed miR-34a at N/P ratios above 18, as probed by gel electrophoresis, and the ζ potential of
micelles decreased to 10.4 ± 1.6 mV with the mean particle size increased to 101.4 ± 0.7 nm. TEM
of micelles presented spherical particles. Upon oxidation of the boronic acid group by ROS such
as H2O2 solution at 0.25 mM for 1 h, miR-34a could be released from the micelles and their
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morphologies were collapsed as shown in TEM image, demonstrating the ROS-responsive release
of miR-34a (Figure 2.3 B-C). We investigated the ROS-triggered degradation of micelles by 1H
NMR as well. Micelles in D2O showed only the PEG peak (Figure 2.3 D), however peaks of 4hydroxymethyl phenol appeared, the intensity increased with incubation time and ζ potential
altered to 3.67 ± 0.28 mV, indicating the disassembly of micelles (Figure 2.3 D). Additionally,
elevated ROS production induced by volasertib can in turn promote the degradation of micelles,

Figure 2.3

Characterization of micelles. (A) Particle size distribution and morphology of

nanoparticles. (B) ROS responsiveness confirmed by a transmission electron microscope
(TEM). (C) Gel electrophoresis to confirm miRNA condensation and ROS responsive miRNA
release. (D)1H NMR spectra of PEG-B-PAEBEA micelles after H2O2 treatment in D2O. (E)
ROS production. (F) Cellular uptake of lipofectamine/FITC-miRNA and polymer/FITCmiRNA. G) FRET effect is demonstrated via the reduction fluorescence intensity of donor at
520 nm with increased fluorescence of acceptor at 600 nm.
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Figure 2.4 Biocompatibility of polymer in pancreatic cancer cell lines.

and further increase the release of small molecules and genes (Figure 2.3 E). Moreover, the
polymeric micelles improved intracellular delivery of miRNA, compared to the commercial
transfection reagent, lipofectamine 2000 (Figure 2.3 F). The critical micelle concentration (CMC)
of micelles was determined to be 2.0 μg/mL using pyrene as a fluorescent probe.
To further ascertain miR-34a loading in micelles, FRET measurement was performed, where
FITC was utilized as a donor conjugated to miR-34a (FITC-miR-34a), Rhodamine was employed
as an acceptor loaded in micelles. The maximal fluorescence intensity at 520 nm of FITC (donor)
from dual-labeled micelles carrying miR-34a and volasertib were significantly reduced, whereas
the fluorescent intensity at 600 nm was increased compared to FITC-labeled miR-34a, which
demonstrates an effective energy transfer from the donor to acceptor in the micelles (Figure 2.3
G).
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2.4.3 Synergistic effect of volasertib and miR-34a and apoptosis
PEG-B-PAEBEA showed high biocompatibility and was suitable for co-delivery of volasertib
and miR-34a (Figure 2.4). The cytotoxicity of volasertib and its combination with miR-34a on
pancreatic cancer cell lines was carried out as a function of volasertib or miR-34a concentrations.

Figure 2.5 Effect of volasertib and miR-34a on pancreatic cancer. (A-D) Cytotoxicity induced by
volasertib alone (E-H) Cytotoxicity caused by the combination of volasertib and miR-34a. (I)
Effect of miR-34a and volasertib on apoptosis. MIA PaCa-2R cells were treated with micelles
loaded with miR-34a, volasertib or their combination. Results are presented as the mean ± S.D. (n=
3). (J and K) Effect of ROS inhibition triggered by DTT on cytotoxicity in pancreatic cancer cells.
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Figure 2.6 Flow cytometry analysis of apoptosis induced by miR34a and volasertib.

combination with miR-34a was decreased by ~2-4.5 fold, compared to volasertib alone and the
combination of volasertib and scrambled miRNA (Figure 2.5 E-H). Meanwhile, CI values obtained
after combination treatment of volasertib and miR-34a were 0.1-0.7 (less than 1), indicating the
synergistic effect of the small molecule and miRNA. Quantitative apoptosis analysis by flow
cytometry using Annexin V-Cy5/PI apoptosis detection kits also indicated that combination of
volasertib and miR-34a with total apoptotic cells of 55 % exhibited higher apoptotic activity in
contrast to other groups (Figure 2.5 I and 2.6). Accordingly, micelles carrying miR-34a and
volasertib were capable of inducing apoptosis with high efficiency. However, once the ROS was
eliminated by a scavenger dithiothreitol (DTT), micelles carrying miR-34a and volasertib displayed
no efficiency compared to the group without DTT pretreatment, which also suggested the ROS
responsive release of volasertib and miR-34a contributed to the therapeutic effect in pancreatic
cancer cells (Figure 2.5 J-K).
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Figure 2.7 Colony formation assay, cell cycle, effect on tumor spheroids and migration assays. (A)
Colony assay after treatment of MIA PaCa-2R cells with micelles carrying miR-34a, volasertib or
their combination. The cells treated with micelles carrying scrambled miRNA and volasertib were
also used control. (B) Cell cycle analysis in MIA PaCa-2R cells. (C) Effect of different formulations
on 3D tumor spheroids. Migration inhibition investigated by scratch wound healing assay (D) and
transwell chamber assay (E), respectively.

2.4.4 Colony assay and cell cycle
To determine whether the combination of volasertib and miR-34a has greater effect on longterm anticancer therapy, we studied volasertib, miR-34a and their combination using scrambled
miRNA as a negative control in MIA PaCa-2R cell line with final concentration of 100 nM for
volasertib and 100 nM for miR-34a, respectively. A significant decrease in the density of colony
was observed with the combination treatment compared to small molecule volasertib alone (Figure
2.7 A). The lower colonies indicated an improved therapeutic efficacy of the combination of
volasertib and miR-34a, due to their synergistic effect.
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PLK1 regulates the cell division cycle during late G2 and M phase and volasertib is a highly
potent PLK1 inhibitor, resulting in G2/M cell cycle arrest followed by programmed cell death in
cancer cell lines. Combination of volasertib and miR-34a demonstrated the strongest ability in
arresting MIA PaCa-2R cells in the G2/M phase among all tested samples. Volasertib and
combination group progressively induced G2/M arrest in MIA PaCa-2R cells, with significantly
parallel decrease of G1 population (Figure 2.7 B and 2.8).

Figure 2.8 Flow cytometry analysis of cell cycle in MIA PaCa-2R cells

2.4.5 Therapeutic efficacy in 3D tumor spheroids and Migration inhibition
The 3D tumor spheroid sizes in control and scrambled miRNA groups were increased after
treatment. In contrast, miR-34a could slightly decrease the size of tumor spheroid. Notably, free
volasertib and micelles encapsulating volasertib exhibited similar results in inhibiting the growth
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of tumor spheroids, while micelles formulating miR-34a and volasertib could significantly reduce
the spheroid size and consequently lead to the collapse of tumor spheroids (Figure 2.7 C). These
results indicated that miR-34a and volasertib loaded micelles displayed significant inhibition on
tumor spheroid-growth.
On the other hand, the migration of cancer cells was predominant element leading to cancer
recurrence. Compared to PBS control group and scrambled miRNA did not suppress cell migration
and partially closed the wound after 48 h. In contrast, miR-34a and combination of miR-34a and

Figure 2.9 Molecular mechanism for the synergistic effect of volasertib and miR-34a. (A-E)
miR-34a expression level determined by qPCR after treatment of HPDE, MIA PaCa-2, MIA
PaCa-2R, Capan-1 and Capan-1R cell lines. (F) Western blotanalysis of Bcl-2, PLK1 and c-myc
in MIA PaCa-2 and MIA PaCa-2R cell lines. (G and H) PLK1 and c-myc mRNA expression
levels determined by qPCR. PBS was used as control (n=3, *p < 0.05, **p < 0.01 and ***p < 0.001).
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volasertib displayed little migration after 24 h and caused reduction of migration after 48 h (Figure
2.7 D-E), thereby indicating the efficient intracellular delivery of miR-34a to cancer cells.

2.4.6 Molecular mechanisms of volasertib and miR-34a
miR-34a expression was significantly lower in pancreatic cancer cell lines compared to normal
pancreatic cancer HPDE cell line (Figure 2.9 A). After transfection with miR-34a mimics, miR34a expression level was enhanced by 6 to 10- fold in MIA PaCa-2 cells (Figure 2.9 B-E). On the
other hand, PLK1 expression level was profoundly suppressed in MIA PaCa-2 cells after incubation
with volasertib in 5 and 80 nM, respectively, while higher concentration (80 nM) was needed to
inhibit PLK1 expression level in MIA PaCa-2R cells (Figure 2.9 F and G).
Bcl-2 has shown to have a dominant role in the survival of cancer cells. miR-34a downregulated
Bcl-2 expression, further leading to inhibition of proliferation and enhancement of apoptosis in
cancer cells (Figure 2.9 F). The treatment of volasertib, miR-34a and their combination contributed
to significant suppression of c-myc expression as well in pancreatic cancer cell lines (Figure 2.9 F
and H), indicating that c-myc was the common target of volasertib and miR-34a, leading to the
synergistic effect of volasertib and miR-34a in pancreatic cancer.

2.4.7 Biodistribution studies
Following systemic administration to NSG mice harboring orthotopic pancreatic tumors, we
compared the delivery and retention of free Cy5.5 and Cy5.5 labeled micelles to evaluate whether
micelles could accumulate in solid tumors. Due to the short half-life of Cy5.5 [29], the NIR signal
intensity was dimmer and disappeared rapidly in mice injected with free Cy5.5. In contrast, robust
fluorescence intensity was obtained at the tumor sites within 4 h of Cy5.5 labeled micelles injection,
following which the signal intensity was sustained for 24 h (Figure 2.10 A). In addition, the liver,
kidney and spleen were also major sites of micelles distribution (Figure 2.10 B-D).
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Figure 2.10 Biodistribution of micelles in vivo. (A) Real-time biodistribution of free Cy5.5 and
Cy5.5 labeled micelles at 1, 2, 4, 8, 24 h (n=3). Quantified accumulation of (B) Cy5.5 labeled
micelles and (C) free Cy5.5 in major organs, including heart, liver, spleen, lung, kidney and tumor
(n=3). (D) Quantified accumulation of Cy5.5 labeled micelles and free Cy5.5 in plasma (n=3). In
plasma, Cy5.5 signal intensity in Cy5.5-micelles injected mice may be from both Cy5.5-micelles
and cleaved Cy5.5 dye.

2.4.8 Antitumor activity
Systemic administration was repeated every 3 days for up to 7 repetitions. Orthotopic tumor
growth was monitored by IVIS bioluminescence imaging, demonstrating significantly slower
tumor growth by treatment with combination micelles compared to saline, free volasertib, miR-34a,
volasertib loaded micelles (Figure 2.11 A and B). This su1ggested that combination of miR-34a
and volasertib elicit a potent antitumor efficacy. No reduction in body weight or morbidity was
observed in mice (Figure 2.11 C), indicating that micellar formulations of volasertib and miR-34a
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were well tolerated. The pathological changes in mouse vital organs were compared among the
groups and representative micrographs of H&E staining proved negligible systemic toxicity of the
formulations as no damage or inflammation was observed (Figure 2.12).

Figure 2.11 Antitumor efficiency in vivo. (A) Bioluminescence images of tumors and isolated
tumor images at the end of the experiment. (B) Tumor weight after treatment with the various
formulations (n = 5, *P < 0.05, **P < 0.01 and ***P < 0.001). (C) Body weight. (D) H&E staining,
Ki67 and cleaved caspase 3 analysis of the tumor specimens. (E) Bcl-2, PLK1 and c-myc expression
determined by Western blot assay. (F) miR-34a, (G) PLK1 and (H) c-myc expression level in tumor
was determined by PCR assay (n = 3, **P < 0.01 and ***P < 0.001).
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Figure 2.12 Representative histological images from retrieved tissues

Tumor tissue sections from different treatment groups were examined by H&E staining and
immunohistochemistry (IHC) staining. In comparison with the morphological characteristics of
H&E stained tissue sections of saline-treated tumors that contained dense carcinoma cells, tumor
cell density in combination micelles-treated tumors was significantly decreased with necrotic tumor
cell areas (Figure 2.11 D). Utilizing an IHC staining for the detection of cleaved caspase 3, we
observed notable apoptotic cell death in combination micelles-treated mice, compared to free
volasertib, miR-34a and volasertib loaded micelles, respectively. Representative IHC images are
shown in Figure 2.11 D. Ki-67 is a marker of proliferation and its staining showed marked
differences between different treatment groups. There was remarkable decrease in the number of
Ki-67 positive proliferating cells in the tumor of the mice treated with combination micelles than
other groups (Figure 2.11 D). Therefore, effective induction of the apoptotic cell death and
profound inhibition of tumor cell proliferation contributed to the antitumor effect in mice. As
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depicted in Figure 2.11 F, miR-34a was considerably upregulated in miR-34a complexed micelles
and the group treated with micelles loaded with volasertib and miR-34a and that is ascertained the
downregulation of Bcl-2 and c-myc in tumor tissues by Western blot and PCR analysis (Figure
2.11 E, G and H). We further confirmed this by quantifying the Western blot bands of Figure 2.11
E by using ImageJ 1.5a (Java 1.8.0_112 (64 bit)) and the results are shown in Figure 2.13.
Moreover, the downregulation of PLK1 induced by volasertib contributed notable c-myc
suppression in tumor sites as well. According to those results, the combination of miR-34a and
volasertib can restore miR-34a expression level, sensitize the cells to chemotherapy, further exhibit
synergistic effect in pancreatic cancer via c-myc, leading to tumor growth suppression and
apoptosis.

Figure 2.13 Quantification of Western blot bands for Bcl-2, PLK1 and c-myc expression by ImageJ
1.5a (Java 1.8.0_112 (64 bit)) of tumors isolated from mice.

2.5. Discussion
Several nanocarriers have been reported to enhance drug delivery to the tumor after systemic
administration. However, most of the current nanoparticle platforms are rarely used for co-delivery
of small molecules or oligonucleotides. Previously, we developed nanocarriers capable of carrying
small molecules and miRNA simultaneously and evaluated their delivery efficacy in subcutaneous
and orthotopic tumor mouse models. Compared to polycarbonate which we used in our previous
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studies, polyaspartate has the following advantages: 1) it is stable during synthesis and postmodification; 2) it is compatible with ring-opening polymerization (ROP) protocols with functional
alcohols; 3) one-step synthesis of monomer for copolymerization; 4) it avoids a two-step reaction
that is deprotection with H2 and subsequent coupling in the presence of EDC/HOBt for replacement
of pendent benzyl groups by simply mixing polyaspartate and tertiary amines; 5) micelles can be
formed by simply dissolving lyophilized polymer in aqueous solution, making it a highly attractive
platform for drug delivery.
Smart polymers capable of responding to the stimuli intrinsic to a tumor environment have
emerged as efficient nanocarriers for the treatment of cancer [30]. Elevated rates of ROS have been
detected in most cancers, and the levels of intracellular ROS in cancer cells are unique biological
stimuli that can be utilized for efficient and targeted drug delivery to cancer cells [28, 31]. Boronic
acid has been extensively used for detection of H2O2 in vitro and in vivo, and the integration of
these functional moieties in the polymeric backbone has been reported [32, 33]. This mechanism
depends on the oxidation-triggered hydrolysis of the boronic ester to a phenol and subsequent
degradation of nanoparticles [33], leading to the release of therapeutic agents. Meanwhile, phenyl
boronic acid (PBA) is also known as Lewis acid, which renders donor-acceptor interaction, also
called coordination bonding with various amines. The donor-acceptor bond energy is much stronger
than non-specific hydrophobic interactions, and undesired drug aggregation can be evitable during
this process [26].
Volasertib with two tertiary amines in the piperazine group could be encapsulated by PEG-BPAEBEA via specific nitrogen-boronic coordination instead of hydrophobic interaction [26]. More
importantly, upon the oxidation of boronic acid group of PEG-B-PAEBEA, the positive quaternary
amines could alter to tertiary amines with no loading capacity (Figure 2.3 D) [26, 32], facilitating
the release of miR-34a and volasertib simultaneously (Figure 2.1). With the elimination of ROS
by DTT a well-known ROS scavenger [34], volasertib micelles exhibited no effect to cancer cells

60

(Figure 2.4 J-K) [35, 36], further indicating the release of volasertib is in a ROS-dependent manner.
Additionally, volasertib could boost ROS levels which in turn accelerated the degradation of PEGB-PAEBEA (Figure 2.1 and Figure 2.3 E), thus a positive feedback loop was established to
enhance the antitumor efficacy while minimize systemic toxicity.
The potential challenges facing NPs include rapid clearance by the mononuclear phagocyte
system (MPS), vehicle-related cytotoxicity, and elicitation of cytokine response caused by the
activation of toll-like receptors (TLRs) [37, 38]. However, the rational design of the polymer/carrier
could be used for addressing these limitations. For example, micelles with particle size below 100
nm modified by PEG on the surface can prolong the circulation by decreasing serum protein
adsorption and preventing MPS recognition [39, 40]. The micelles designed in this study were
decorated by PEG as the hydrophilic surface with particle size around 100 nm, providing them a
great chance for extended circulation and tumor accumulation.
By whole-body fluorescence imaging, mice injected with free Cy5.5 showed maximal tumor
fluorescence at 2 h followed by rapid clearance with time. The positive quandary amine of Cy5.5
might increase its binding to plasma proteins, therefore biodistribution of free Cy5.5 showed little
liver and kidney accumulation with low tumor retention at 8 h [41, 42]. In contrast, mice treated
with Cy5.5-conjugated micelles showed excellent tumor accumulation of micelles even at 24 h post
systemic administration, demonstrating that the Cy5.5 was not removed from micelles and the high
intensity in the tumor was resulted from high accumulation of micelles, not free Cy5.5.
High expression of PLK1 and low expression of miR-34a is associated with short survival rate
in pancreatic cancer patients [14, 43, 44]. PLK1 is essential for stabilizing Myc family oncoproteins
and miR-34a can affect cell proliferation through repression of Myc [45]. PLK1-Myc feedforward
activation loop participates in PDAC progression and Myc amplification in pancreatic cancers
predicts poor prognosis and resistance to therapy [17, 46, 47]. Altogether, c-myc downregulation
can contribute to the inhibition of pancreatic cancer development [14, 47]. PLK1 inhibitor
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volasertib could not only downregulate PLK1 to arrest cell cycle of tumor cells, but also reduce
downstream c-myc phosphoraylation then inhibit c-myc transcription [46]. Meanwhile, miR-34a
can target c-myc and Bcl-2 directly [45, 48]. To date, volasertib and miR-34a was tested alone in
clinical trial, but their combination has not been evaluated yet [6, 49]. Herein, we investigated
efficacy of combination of those two anticancer agents encapsulated by PEG-B-PAEBEA in
orthotopic pancreatic tumor-bearing mice. Due to the synergistic effect of volasertib and miR-34a,
downregulating of PLK1 while upregulating miR-34a resulted in significant suppression of their
common target c-myc and pronounced tumor inhibition, which suggests the potential of
combination of volasertib and miR-34a could be translated as a strategy in future pancreatic cancer
therapy [17]. Moreover, H&E staining validated the formulations were well tolerated and did not
display any signs of tissue or cellular damage such as ballooning degeneration of hepatocytes,
increased alveolar wall thickness or cellular infiltration in lung tissue, myocardial fibrillar loss and
vacuolation in heart tissues, edema, tubular vacuolization or tubular dilation with hemorrhagic
areas in the kidney, or increased numbers of granulocytes in the spleen (Figure 2.12) [50, 51].
Those results support that our ROS-triggered polymeric micellar system has potential to overcome
the limitations and adverse effects of gene and anticancer drug delivery.
In conclusion, we have demonstrated a ROS-labile polymer PEG-B-PAEBEA which was
strongly positive charged can be self-assembled to micelles and effectively packaged volasertib
and miR-34a into micelles but became neutral charged once triggered by intracellular ROS. The
micelles successfully delivered volasertib and miR-34a in a controlled manner so that they can be
released into the tumor sites accurately, resulting in high tumor regression compared to single drugloaded micelles. Without complicated polymer design or drug modification, PEG-B-PAEBEA
provided a facile and robust strategy with high biocompatibility for the encapsulation of
hydrophobic drugs and genes.
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Chapter III
Dual Responsive Micelles Capable of
Modulating miRNA-34a to Combat
Taxane Resistance in Prostate Cancer
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3.1 Abstract
There is a direct correlation between increase in the number of cancer stem cells (CSCs)
and chemoresistance that impedes successful chemotherapy. Synergistic therapy by targeting
both bulk tumor cells and CSCs has shown promise in reversing chemoresistance and treating
resistant prostate cancer. Herein, we demonstrated the fabrication of a pH and glutathione
(GSH) sensitive nanocarrier for co-delivery of docetaxel (DTX) and rubone (RUB), a miR-34
activator for targeting CSCs, for the treatment of taxane resistant (TXR) prostate cancer. DTX
loaded P-RUB (DTX/P-RUB) micelles were prepared by encapsulating DTX into pH
responsive diisopropylaminoethanol (DIPAE) and GSH responsive RUB prodrug conjugated
polycarbonate-based micelles. The self-assembled DTX/P-RUB micelles displayed good
stability in vitro and could efficiently target to tumors by enhanced permeability and retention
(EPR) effect. After endocytosis by tumor cells, the micelles underwent expansion and
disassembly due to the protonation of DIPAE and GSH induced cleavage of disulfide bond in
acidic endocytic vesicles, resulting in fast release of DTX and RUB. The released RUB then
upregulated the intracellular miR-34a, which then affected the expression of proteins involved
in chemoresistance, thus sensitizing the tumor cells towards DTX and further leading to
significant inhibition of TXR tumor progression. Thus, DTX/P-RUB micelles have the
potential to treat TXR prostate cancer. By taking advantage of this dual responsive strategy,
the successful delivery of many other hydrophobic drugs can be achieved for cancer treatment.
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3.2 Introduction
Development of chemoresistance poses a serious problem in cancer chemotherapy [1,2].
The mounting evidence indicates the increased number of cancer stem cells (CSCs) after
repeated treatments mainly accounts for the acquired chemoresistance because of their
inherent tumor initiating and self-renewal capacity, more chemo-resistant property and key
roles in tumorigenesis, progression and metastasis [3-6]. MicroRNAs (miRNAs) regulate
CSCs as well as normal stem cells and dysregulation of miRNAs in CSCs has been contributed
to chemoresistance [7-11]. Tumor suppressor miR-34a recently received increasing attention
and is a key negative regulator of tumorigenic prostate CSCs [7,12,13]. A chalcone derivative,
2′-hydroxy-2,4,4′,5,6′-pentamethoxychalcone, termed as rubone (RUB), was found to
upregulate the intracellular miR-34a in hepatocellular carcinoma, resulting in significant tumor
shrinkage [14]. Unfortunately, the in vivo delivery of oligonucleotide-based miRNA and highly
hydrophobic drugs remains a challenge due to potential off-target toxicity, rapid clearance,
poor cellular uptake or in vivo instability [14-17]. Over the past several decades, nanoparticles
have received tremendous attention in cancer therapy for its ability to improve aqueous solubility
and stability of hydrophobic drugs and nucleic acids, prolong blood circulation half-life and
increase deposition in the target tissues via the enhanced permeability and retention (EPR) effect
[18-22].
Although some nanoparticles have been designed to address chemoresistance [23-26], we
noted that only a few have been exploited to reverse the drug resistance by targeting the CSCs by
regulating the level of miRNAs with small molecules. Deng et al. reported through encapsulation
of RUB in cationic micelles, the RUB exhibits higher water solubility and higher potency in
antitumor activity [27]. We previously reported the co-delivery of paclitaxel and RUB through
encapsulation in poly (ethylene glycol)-block-poly (2-methyl-2-carboxyl-propylene carbonategraft-dodecanol; PEG-PCD) can be used for the treatment of taxane resistant (TXR) prostate
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cancer by chemosensitizing the prostate cancer cells [28]. Compared with these conventional
nanoparticles, a bio-responsive nanoplatform with excellent biocompatibility, biodegradation and
high drug loading is of growing interest in recent years [29,30], especially for polymer-drug
conjugate delivery system, since insufficient drug exposure due to slow drug release might induce
acquired chemoresistance. It is well documented that tumor has a slightly acidic microenvironment
(6.5-6.8) while the pH value is 5.5-6.5 in early endosomes and 4.5-5.5 in late endosomes/lysosomes
[31,32] and the level of glutathione (GSH) is significantly elevated in tumor cells [33,34]. Thus,
the design of taking advantage of the variations in either redox condition [35-37] or pH value
[30,38-40] or even both [41,42] will be markedly influential on the effectiveness of nanoparticles
by accelerating and maximizing the cargo release. Keeping all these in mind, we have developed a
novel pH and GSH responsive nanoplatform by integrating multi-responsive property to meet the
demands in combating drug resistance in the study. Our polymeric drug delivery system undergoes
rapid drug release at the tumor site upon endocytosis into acidic intracellular compartments where
the low pH value promotes protonation of DIPAE and the abundant GSH induces the cleavage of
disulfide bond, leading to efficient drug release. As proof-of-concept, we selected the microtubule
stabilizer DTX and a miR-34a activator RUB as a combination therapy for treating TXR prostate
cancer [28]. Driven by delicate balance between hydrophobic (i.e., RUB and tertiary amine)
and hydrophilic (i.e., PEG) segments [43] and the ionic interaction (i.e., partially ionized
tertiary amines [44] and carboxylic acids) at physiological pH condition (7.4), the RUB and
DIPAE conjugated polycarbonate (P-RUB) can self-assemble into micelles and encapsulate
DTX into the micellar core by coprecipitation, with pH responsive property conferred by
DIPAE, a tertiary amine [45–47] and GSH responsive property endowed by the attachment of
RUB through 2,2′-dithiodiethanol, a disulfide containing linker [48–50]. We expect such
micellar system could keep its structural integrity and selectively accumulate in TXR tumor
site after administration. Upon endocytosis by tumor cells, the micelles would expand and
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Figure 3.1

dissociate in response to low pH value of endocytic vehicles, thus leading to ultrafast drug
release by consequent sufficient exposure to GSH for the cleavage of disulfide bond, which
would result in successful inhibition of TXR tumor growth. This consequence should be
attributed to the protonation of ionizable amino groups and subsequent breakup of the ionic bonds
in acidic endocytic vehicles (Figure 3.1). The design not only perfectly solves RUB loading issue
(less than 7%) faced by other studies, including ourselves', but also lowers the chance of resultant
chemoresistance induced by sublethal drug exposure.
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3.3 Experimental session
3.3.1 Materials
4′,6′-Dimethoxy-2′-hydroxyacetophenone, 2,4,5-trimethoxybenzaldehyde were purchased
from TCI America. α-Methoxy-ε-hydroxy- poly(ethylene glycol) (mPEG-OH, Mn = 5 kDa)
(mPEG-OH), trimethylamine
(NaOH),

potassium

hydroxide

(TEA), 2-dihydroxyethyl disulfide, sodium hydroxide
(KOH),

N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide

hydrochloride (EDCI), 1-hydroxy-7-azabenzotriazole (HOAt), pyridine, dimethylformamide
(DMF), dichloromethane (DCM), tetrahydrofuran (THF), chlorotriethylsilane (TES-Cl),
imidazole,

1,8-diazabicyclo

[5.4.0]undec-7-ene

(DBU),

benzyl

bromide,

2,2′-

bis(hydroxymethyl)propionic acid and triphosgene were all purchased from Sigma-Aldrich and
used as received. Docetaxel (DTX) was obtained from LC Laboratories. The buffer solutions were
prepared in our lab. Dialysis membrane was obtained from Spectrum Lab. All solvents were of
analytical grade.

3.3.2 Synthesis of RUB-S-S-OH, P-RUB and non-responsive R-RUB
3.3.2.1 Synthesis of RUB-S-S-OH
Step 1. A mixture of 4, 6-dimethoxy-2-hydroxyacetophenone (1.0 g, 5.1 mmol), 2,4,5trimethoxybenzaldehyde (1.0 g, 5.1 mmol) and KOH (8.0 g, 142.9 mmol) in ethanol was
stirred overnight at room temperature. After removal of solvent, the residue was dissolved in
CH2Cl2 (400 mL) and neutralized with 4 M HCl. The organic layer was separated, and the
aqueous layer was extracted with CH2Cl2. The combined organic extracts were washed with
saturated NaHCO3, water and brine, dried over anhydrous Na2SO4, filtered and concentrated.
The crude product was purified by crystallization from EtOH to afford RUB as a yellow solid
(1.37 g, 72%). 1H NMR (500 MHz, CDCl3) δ 14.54 (s, 1H), 8.00 (dd, J1 = 130.2 Hz, J2 =
15.6 Hz, 2H), 7.26 (s, 1H), 7.12 (s, 1H), 6.52 (s, 1H), 6.03 (dd, J1 = 74.5 Hz, J2 = 1.9 Hz,
2H), 3.95 (s, 3H), 3.91 (s, 6H), 3.89 (s, 3H), 3.83 (s, 3H).
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Step 2. Chlorotriethylsilane (1 g, 6.5 mmol) was added to a mixture of 2-hydroxyethyl
disulfide (1.0 g, 6.5 mmol) and imidazole (0.46 g, 6.8 mmol) in DCM at 0 °C. The resulting
mixture was stirred overnight at the room temperature, filtered to remove solid precipitate and
concentrated. The residue was dissolved in CH2Cl2, washed with saturated NaHCO3, water and
brine, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified
by flash column chromatography (hexane: EtOAc = 1:1) to afford compound 1 as colorless
oil (0.6 g, 60%). 1H NMR (500 MHz, CDCl3) δ 3.89 (dt, J1 = 13.4 Hz, J2 = 6.3 Hz, 4H),
2.90-2.81 (m, 4H), 2.07 (t, J = 6.3 Hz, 1H), 0.97 (t, J = 7.9 Hz, 9H), 0.62 (q, J = 7.9 Hz,
6H).
Step 3. The solution of triphosgene (59 mg, 0.3 mmol) in DCM was added to the mixture of RUB
(374 mg, 1.0 mmol) and DMAP (610 mg, 5 mmol) in DCM. The mixture was stirred for 1 h before
the solution of compound 1 (280.875 mg, 1.05 mmol) in CH2Cl2 was added. After stirring
overnight, the solvents were removed and the residue was re- dissolved in CH2Cl2, washed with
water, dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by
column chromatography (Hexane: EtOAc = 1:1) to afford compound 2 as a yellow solid (0.43 g,
65%).
Step 4. A mixture of compound 2 (0.4 g, 0.6 mmol) in ethanol with tetrabutylammonium fluoride
(TBAF) was stirred at the room temperature for 1 h before neutralized with saturated NaHCO3
aqueous solution. The mixture was then diluted with CH2Cl2 and washed with water and brine,
dried over anhydrous Na2SO4, filtered and concentrated. The crude product was purified by silica
chromatography (Hexane: EtOAc = 1:3) to afford RUB-S-S-OH as an orange solid (282.54 mg,
85%). 1H NMR (499 MHz, CDCl3): δ 7.34 (dd, J1 = 374.7 Hz, J2 = 16.1 Hz, 1H),
6.86 (dd, J1 = 145.1 Hz, J2 = 129.0 Hz, 1H), 6.42 (dd, J1 = 18.8 Hz, J2 = 1.9 Hz, 1H),
4.42 (t, J = 6.6 Hz, 1H), 3.93 (s, 1H), 3.87-3.83 (m, 3H), 3.80 (s, 1H), 2.93 (t, J = 6.6 Hz,
1H), 2.86 (t, J = 6.1 Hz, 1H), 2.54 (t, J = 6.1 Hz, 1H). 13C NMR (126 MHz, CDCl3): δ
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191.74, 161.89, 158.99, 154.47, 152.91, 152.50, 149.95, 143.24, 140.07, 126.11, 116.12,
115.28, 111.24, 99.68, 97.11, 96.88, 66.43, 60.41, 56.46, 56.39, 56.04, 56.03, 55.65, 41.45,
36.60.
3.3.2.2 Synthesis of P-RUB
Step 1. 2, 2-bis(hydroxymethyl)propionic acid (22.51 g, 0.168 mol) and KOH (9.4 g, 0.168 mol)
was dissolved in DMF by heating the solution to 100 °C. Benzyl bromide (34.34 g, 0.202 mol) was
then added dropwise to the above solution and the mixture was kept stirring at 100 °C overnight.
After removal of solvent, the residue was re-dissolved in EtOAc, washed with H2O (4 x 200 mL),
dried over anhydrous Na2SO4, filtered and concentrated. The crude product was recrystallized from
toluene to afford benzyl 2,2-bis(methylol)propionate as a white solid (26.34 g, 70%).
Step 2. A solution of triphosgene (7.425 g, 25 mmol) in CH2Cl2 was added dropwise to a
solution of benzyl 2, 2-bis(methylol)propionate (11.25 g, 50 mmol) and pyridine (25 mL) in
CH2Cl2 (150 mL) at −78 °C under N2 atmosphere over 1 h. The resulting mixture was stirred
at room temperature for 2 h before being quenched with saturated ammonium chloride
solution. The organic layer was separated, and the aqueous layer was extracted with CH2Cl2
(2 × 100 mL). The combined organic extracts were washed with 1 M HCl (3 × 150 mL),
saturated sodium hydrogen carbonate aqueous solution and brine, dried over anhydrous
Na2SO4, filtered and concentrated. The crude product was further purified by recrystallization
in ethyl acetate to afford 2-methyl- 2-benzyloxycarbonyl-propylene carbonate (MBC) as a
white solid (9.37 g, 75%).
Step 3. The catalyst 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) was added to a stirred solution
of mPEG-OH (1.0 g, 0.2 mmol) and MBC(1.8 g, 7.2 mmol) in CH2Cl2. The resulting mixture
was stirred for 4 h before being quenched by benzoic acid. The mixture was then
concentrated and triturated with cold isopropanol (IPA). The resulting solid was collected by
filtration and dried to afford PEG-PBC (2.154 g, 85%).
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Step 4. To a mixture of PEG-PBC in THF and methanol (1:1) was added 10% w/w Pd/C.
The reaction was stirred for 24 h under H2 balloon. The reaction suspension was then filtered
and the filtrate was concentrated to afford poly (ethylene glycol)-block-poly (2-methyl-2carboxyl-propylene carbonate) (PEG-PCC) in a yield of 97%.
Step 5. A mixture of PEG-PCC (Mw 9800, 100 mg, 0.01 mmol), RUB-S-S-OH (33.24
mg, 0.065 mmol), HOAT (67.5 mg, 0.5 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) (96 mg, 0.5 mmol) and triethanolamine (TEA) (60.6 mg, 0.6 mmol) in anhydrous
DMF was stirred for 24 h under N2 before diisopropylamino ethanol (73 mg, 0.5 mmol) was added.
The reaction was continued for another 24 h and then triturated with cold isopropanol. The
resulting solid was collected by filtration and dialyzed against acetone: methanol (1:1) to give poly
(ethylene

glycol)-block-poly

(2-methyl-2-carboxyl-propylene

carbonate-graft-

diisopropylaminoethanol-grafted-RUB-S-S-OH) (P-RUB) as a yellow solid (104 mg, 73%).
The successful conjugation of RUB-S-S-OH and DIPAE on P-RUB was confirmed by 1H NMR
spectra. 5 molecules of RUB were calculated to be conjugated on each polymer chain. The weight
percentage of RUB in the conjugate was further confirmed by HPLC method (Column:
Phenomenex Aqua 5U C18; temperature = 25 °C; flow rate = 0.7 mL/min; mobile phase = 4:1
vol/vol mixture of acetonitrile and water).
3.3.2.3 Synthesis of non-responsive P-RUB
Nonresponsive P-RUB was synthesized in a similar way by conjugating RUB and
dodecanol to the pendant carboxylic acid groups of PEG-PCC via esterification. The chemical
structure of nonresponsive P-RUB was determined by 1H NMR in CDCl3 and the weight
percentage of RUB in the conjugate was calculated by integration of the peak and HPLC
method (Column: Phenomenex Aqua 5U C18; temperature = 25 °C; flow rate = 0.7 mL/ min;
mobile phase = 4:1 vol/vol mixture of acetonitrile and water).
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3.3.3 Preparation and characterization of pH and GSH dual responsive P- RUB micelles
The pH and GSH responsive micelles were prepared using nano-precipitation method. Briefly,
5 mg P-RUB or Cy5.5 labeled P-RUB were first dissolved in 250 μL of acetone. The resultant clear
solution was added into 1 mL of PBS under stirring for 1 h followed by evaporation of residual
acetone under vacuum. DTX encapsulated P-RUB micelles were prepared using a similar way that
0.6 mg DTX was co-dissolved with 5 mg P-RUB in 250 μL of acetone. The drug loading and
loading efficiency were determined using HPLC method (Column: Phenomenex Aqua 5U C18;
temperature = 25 °C; flow rate = 0.7 mL/ min; mobile phase = 4:1 vol/vol mixture of acetonitrile
and water) by use of a UV detector at 228 nm for DTX and 324 nm for RUB. The pH and GSH
responsive property of P-RUB micelles was determined by measuring particle size and ζ potential
using a Malvern Zetasizer at a 90° angle after incubation of P-RUB micelles in biomimetic
environment of pH 5.0, 10 mM GSH at 37 °C. The morphology and its change of P-RUB was
determined by a transmission electron microscope (TEM). In vitro RUB release from dual
responsive and nonresponsive P-RUB micelles was carried out under different conditions (PBS at
pH 7.4 with or without 10 mM GSH, acetate buffer at pH 5.0 with or without 10 mM GSH). For
DTX release, the dialysis bags (MWCO: 14000 Da) were loaded with DTX/R-RUB micelles and
were then dipped into a large excess of buffer solutions and gently shaken at 37 °C at a speed of
100 rpm (n = 3). At predetermined time points, 100 μL of solution was taken out. The buffers were
changed periodically to maintain the sink condition. RUB and DTX concentrations were
determined by HPLC under the following conditions: Phenomenex Aqua 5μ C18 column (250 ×
4.6 mm) at 25 °C and flow rate of 0.7 mL/min. A mixture of acetonitrile and water (4:1 vol/vol)
was used as the mobile phase, injection volume was 20 μL and wavelengths were 229 and 325 nm
for DTX and RUB, respectively.

3.3.4 Determination of critical micelle concentration (CMC)
The CMC of P-RUB micelles was determined using pyrene as a fluorescent probe. P-RUB
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micelles were prepared as aforementioned and diluted to different concentrations (1 × 10−5
∼0.5 mg/mL). Then pyrene in acetone (1.2 × 10−6 M) was added to P-RUB solutions and

shook for 24 h at the room temperature. The fluorescence emission spectra of P-RUB micelles

were recorded by using a spectrofluorometer with an excitation wavelength at 334 nm. The
ratio of emission intensity (I384/I373) was plotted against the logarithm of P-RUB mass
concentrations.

3.3.5 Cellular internalization and subcellular fate
DU145-TXR and PC3-TXR cells were kindly provided by Dr. Evan T. Keller from the
University of Michigan in 2010. These cells were cultured in 100 nM containing complete RPMI
1460 medium supplemented with 10% of fetal bovine serum (FBS) and 1% antibiotics and
antimycotics. Both these cell lines were cultured at 37 °C under a humidified atmosphere with 5%
CO2 supply. For cellular internalization studies, these cell lines (5 × 104) were first seeded in a
coverslip chamber respectively and cultured for 24 h. Then, the cells were incubated with fresh
media containing Cy5.5 labeled P-RUB micelles for 6 h at 37 °C in dark. We also used Cy5.5labeled non-responsive P-RUB micelles as a positive control. The cells were then washed with ice
cold PBS thrice and fixed with 4% paraformaldehyde. Finally, the cells were stained with 4′,6diamidino-2-phenylindole) (DAPI) and visualized using the confocal laser scanning microscopy
(CLSM). To track intracellular molecular delivery, PC3-TXR and DU145-TXR (5 × 104) were
first seeded in a coverslip chamber respectively and cultured for 24 h. Then, the cells were
incubated with fresh media containing Cy5.5 labeled P-RUB micelles as well as Cy5.5 labeled
nonresponsive P-RUB micelles for 6 h at 37 °C in dark, followed by the stain of Lysotracker,
Hoechst 44432 and immediately imaged by CLSM.

3.3.6 RT-PCR and western blot analysis
The total RNA was isolated from DU145-TXR and PC3-TXR cells using miRNeasy
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isolation kits (Qiagen, Valencia, CA) after incubation with different concentrations of P-RUB
for 48 h. Then, total RNA was reverse transcribed to cDNA using TaqMan qRT-PCR kit (Life
Technologies, Carlsbad, CA). cDNA was amplified on real-time PCR using SYBR Green dye
universal master mix and miR-34a primer on a Light Cycler 480 (Roche, Indianapolis). U6
was used as a housekeeping gene and relative amount of miR-34as was calculated using the
crossing point (Cp) value.
To determine protein expression, the cells (3 × 105) treated with P-RUB (5, 10, 25, 50 μM)
for 48 h were lysed with RIPA buffer. The extracted protein concentration in each sample was
determined by BCA assay and then adjusted to the same level and transferred to poly- vinylidene
difluoride (PVDF) membrane. After incubation with primary antibody (1:500) at 4 °C overnight,
IR fluorescent dye labeled secondary antibodies (925-68074 or 925-32213, Li-COR) was added,
followed by analysis using Licor Odyssey system (LI-COR Biotechnology, Lincoln, NE). The
antibodies purchased from Santa Cruz Biotechnology were used in the study include anti-P-gp,
anti-Elk-1 (sc-355), anti-SIRT1 (sc- 15404), anti-TAp73 (sc-7957), anti-Bax (sc-6236), anti-βactin (sc- 1616).

3.3.7 Inhibition of CSC proliferation by P-RUB micelles
DU145-TXR and PC3-TXR cells (2.5 × 105/well) were seeded in 6 well plates. After 24 h,
both of the cell lines were treated with P-RUB micelles containing 5, 10 and 25 μM of RUB and
+

incubated for 48 h. Then, the cells were harvested and analyzed for ALDH

stained by Aldehyde

assay kit per the manufacturer's instruction (Stemcell Technologies, Vancouver, Canada) and
further analyzed using an FACSCalibur flow cytometer. GFP-positive and DEAB-treated cells
were used to set up a gated region.

3.3.8 Drug effect on cell cycle of PC3, DU145, DU145-TXR and PC3-TXR
DU145-TXR and PC3-TXR cells (15 × 104/well) were seeded in a 6-well plate,
80

respectively and cultured for 24 h, the medium was replaced with 100 μL of fresh media
containing different treatments, DTX (60 nM for PC3-TXR, 180 nM for DU145 TXR), P-RUB
(10 μM for PC3-TXR, 20 μM for DU145-TXR), and DTX/P-RUB (30 nM/5 μM, 90 nM/10
μM) respectively. After 24 h incubation, the cells were stained with PI/RNase solution and
evaluated with a flow cytometer. Effect of DTX on DU145 and PC3 cell cycle arrest was also
determined.

3.3.9 Cytotoxicity of P-RUB and DTX/P-RUB in 2D and 3D models
For cell viability in a two-dimensional (2D) model, DU145-TXR and PC3-TXR cells (6 ×
103/well) were seeded in 96 well plate, respectively and cultured for 24 h, the medium was replaced
with 100 μL of fresh media containing different treatments as follows: DTX, RUB, P-RUB and
DTX/P- RUB (5, 10, 25, 50 μM). After 48 h incubation, cell viability was evaluated by MTT
assay. For cell viability in 3D model, DU145-TXR cells (8 × 104/well) suspended in 500 μL
media was added to a 24-well plate with 200 μL of 100% Matrigel as basement. After 48 h, the old
medium was replaced with the fresh growth medium containing DTX (180 nM), P-RUB (20 μM),
DTX/P-RUB (90 nM/10 μM), nonresponsive P-RUB(20 μM), and nonresponsive DTX/P-RUB
(90 nM/10 μM), which was replaced every other 2 days for 10 days before analyzing the
therapeutic efficacy.

3.3.10 Biodistribution and anticancer efficacy
All animal study was performed under the guidelines of Institutional Animal Care and Use
Committee (IACUC) at the University of Nebraska Medical Center (Omaha, NE). To monitor the
tumor growth, luciferase expressing PC3-TXR cells were obtained by transducing the cells with
lentiviral particles encoding GFP and luciferase. Orthotopic PC3-TXR bearing nude mouse model
was established by making a midline incision in the lower abdomen of 8 weeks old male nude mice
to expose the dorsal prostate lobe, where 30 μL of PBS containing 1 million cells was injected.
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Three weeks after tumor cell injection, mice with orthotopic tumor were injected with Cy5.5
labeled DTX/P-RUB micelles through a tail vein. The fluorescence signal (excitation: 640 nm;
emission: 710 nm) was detected by using IVIS imaging system (PerkinElmer, Hopkinton, MA) at
1, 3, 6, 12, 24, 48 h. After the final imaging at 24 h and 48 h, the mice were sacrificed. Tumors and
major organs including kidney, heart, spleen, lung and liver were harvested for further ex vivo
imaging. To assess RUB concentration in the tumor, equivalent doses of Cy5.5 labeled P-RUB
and free RUB were intravenously injected into orthotopic prostate cancer bearing mice. Tumors
were harvested at 24h and 48h, respectively, followed by homogenization. The homogenate
was centrifuged at 12,000×g at 20 °C for 10 min. The supernatant was aspirated out and air
dried at 40 °C. Afterwards, 250 μL of acetonitrile and 50 μL of ammonium hydroxide were
added to the tubes and stirred for 20 min. Finally, RUB concentration in the tumors was
determined by LC-MS/MS using Analyst® software on a QTRAP 4000 mass spectrometer.
The separation was achieved on a Shimadzu HPLC, with a Waters C18 column (150 × 3.9
mm, 4 μm) with isocratic elution of water and acetonitrile at a ratio of 35:65 v/v as a mobile
phase at 0.5 mL/min flow rate. An injection volume of 10 μL was used for sample analysis by
LC-MS/MS. The mass spectrometer was operated in the positively multiple reaction
monitoring (MRM) for RUB and internal standard. The following MRM transitions were
monitored: m/z 375.3 for RUB and m/z 197.1 for 2,4,4-trimethoxybenzaldehye. RUB
concentration was calculated using a 1/x2 quadratic regression over a concentration range of
5.0–5000 ng/mL with constant internal standard.
For antitumor efficacy, once the bioluminescence intensity was reached 6 × 106, the mice were
randomly divided into 6 groups, with 6 mice in each group. Then the mice were intravenously
injected with various formulations, including PBS, DTX+RUB, P-RUB, DTX/P-RUB, DTX/PEGPCD and nonresponsive DTX/P-RUB micelles (DTX 5 mg/kg and RUB 25 mg/kg) every other 2
days for 18 days. Tumor bioluminescence and body weights of the mice were recorded once a
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week. At 2nd day after the final injection, the mice were sacrificed. Then miR-34a level in tumors
from each group was determined using miRNeasy isolation and RT-PCR (Qiagen, Valencia, CA).
Besides, the major organs and tumors were collected and fixed in 10% of formalin solution
overnight for following hematoxylin and eosin (H&E) staining and immunohistochemistry for
SIRT1, Ki-67 and cleaved caspase-3. Representative immunohistochemical images were analyzed
using ImageJ to quantify fluorescence intensity. We also determined SIRT1 protein expression in
tumor tissues by Western blot analysis.

3.3.11 Statistical analysis
All the data were presented as the average value ± standard deviation (SD). The statistical
comparison was carried out by one-way ANOVA and a P value < 0.05 was considered to be
statistically significant.

3.4 Results
3.4.1 Synthesis and characterization of P-RUB and non-responsive P-RUB
Dual responsive P-RUB was synthesized via a multi-step process and characterized by 1H
NMR (Figure 3.2). Briefly, RUB was synthesized via aldol reaction, and then a disulfide
containing linker was conjugated to RUB by the formation of carbonate bond, yielding RUB-S-SOH. After that MBC was obtained and copolymerized with mPEG-OH (Mw = 5000) to produce
PEG-PBC, followed by the removal of benzyl protecting groups to produce PEG-PCC with pendant
carboxylic acids. Finally, PEG-PCC was treated with RUB-S-S-OH and DIPAE to afford P-RUB.
Polycarbonate was selected as a block polymer because of its convenience for chemical
functionality, its biodegradability, its biocompatibility and non-toxic consequent products (an
alcohol and carbon dioxide). About 17% of the carboxylic acids reacted with RUB-S-S-OH and
47% with DIPAE based on NMR spectrum. The unreacted carboxylic acids provide opportunity
for further attachment of other components (targeting ligand and chemotherapeutics). Besides, the
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Figure 3.33
1

. Synthetic scheme and

H-NMR spectrum of dual sensitive poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-

propylene carbonate-graft-rubone-graft-diisopropylamino ethanol (P-RUB). The black arrow
indicates the presence of rubone-S-S-OH and diisopropylamino ethanol in poly(ethylene glycol)-

partially ionized carboxylic acids (pKa = 5) and DIPAE (pKa = 9) [43] at physiologic pH
condition (7.4) would form ionic interaction, thus stabilizing the micellar system. RUB content in
the conjugate was calculated to be 12.5 wt% as based on the integration of peak at 3.65 ppm (CH2
of mPEG) and peak at 7.72, 7.03, 6.94,6.49, 6.4(aromatic proton on RUB-S-S-OH) in the NMR
spectrum. For use as a positive control, we also synthesized nonresponsive P-RUB by conjugating
RUB and dodecanol to the polycarbonate backbone. Non-responsive P-RUB was synthesized in a
similar way except that RUB and dodecanol were used to react with PEG-PCC, which was
characterized afterwards by 1H NMR as well (Figure 3.3).
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3.4.2 Particle size and surface morphology of DTX/P-RUB micelles
P-RUB micelles and DTX encapsulated dual responsive and non-responsive micelles were
prepared by nanoprecipitation method. The resultant responsive micelles had sizes of 45.07 ±
0.49 nm and 49 ± 0.26 nm, respectively, determined by dynamic light scattering (DLS) and
showed spherical morphology by TEM （Figure 3.4 A）. Determined by HPLC method, the
content loaded in the polymeric micelle core was relatively high (9%). The polymeric micelles
prepared from PEG-PCC showed a larger size of 250 nm. The hydrophobicity of tertiary amine and
RUB greatly stabilized the micellar structure, resulting in little change in the particle size of PRUB micelles when pH was above 6.5 for 120 h (Figure 3.4 B), implying its ability of
maintaining the structural integrity in the bloodstream and tumor microenvironment. When
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Table 3.161 Particle size distribution, polydispersity (PDI), zeta-potential (ζ) and loading
capacity (LC) of P-RUB micelles.

pH value was decreased to 5.0, micelles swelled to above 400 nm in 2h (Figure 3.4 B).
Meanwhile, we noticed that ζ potential increased from 0.8 ± 0.33 mV to 2.5 ± 0.84 mV when
we decreased the pH from 7.4 to 6.5. In contrast, the ζ potential of non-responsive P-RUB
micelles was −5.2 ± 1.44 mV at pH 7.4 and −5.56 ± 0.88 mV at pH 6.5 (Table 3.1). We
thus assume that P-RUB micelles expanded due to the protonation of DIPAE in acidic
environment since a gradual positive surface charge increment was found. TEM and DLS
were utilized to prove the acid-induced dissociation and expansion of P-RUB micelles under
different conditions. As shown in Figure 3.4 E and F, at pH 7.4, P-RUB micelles showed
spherical morphology with a diameter around 30 nm (TEM). Upon acidification to pH 5.0,
the micelles dissociated as indicated by decreased counting rate by DLS and big spherical
particles was observed with a diameter of around 280 nm by TEM. Meanwhile, the particle
size of the micelles significantly increased (from 49 nm to 900 nm) when incubated with 10
mM GSH for 0.5 h at 5.0 (Figure 3.4 C and D), implying the dissociation of micelles, the
subsequent cleavage of disulfide bond and aggregation formation. Furthermore, this process
took much longer (12 h) when the pH was 7.4. This phenomenon strongly suggests the
facilitated entry of GSH to the micellar core due to the expansion of micelles by protonation of
DIPAEs at low environmental pH value of 5.0. The critical micelle concentration (CMC) of P-RUB
was determined to be 9.12 μg/mL using pyrene as a fluorescent probe. Due to the poor aqueous
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Figure 3.569

solubility of pyrene, it tends to diffuse into the hydrophobic core of micelles, resulting in photophysical property changes.

3.4.3 Drug release
To achieve an ideal therapeutic effect, it is important for DTX/P-RUB micelles to undergo drug
release soon after endocytosis by cancer cells. The drug release profiles of DTX/P-RUB micelles
were then investigated, while using nonresponsive DTX/P-RUB micelles were used as a positive
control. In agreement with the redox sensitive design, only less than 5% of RUB was released from
P-RUB at both physiological pH of 7.4 and lysosomal pH of 5.0 within 24 h. Thus, RUB should
not be released before P-RUB micelles are endocytosed by tumor cells. Upon the addition of GSH,
RUB release was accelerated due to the cleavage of disulfide bond, especially at pH 5 as above
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Figure 3.801 Drug release study.

95% of RUB was released within 8 h, when compared to that at pH 7.4, at which it requires more
than 24 h (Figure 3.5 A). In contrast, there was little release of RUB from non-responsive P-RUB
micelles regardless of change in pH from 7.4 to 5 and GSH (Figure 3.5 B). These results suggest
that rapid increase in RUB release from the dual responsive P-RUB micelles may be due to the
protonation of DIPAEs, leading to the disassembly of micelles, resulting in complete exposure of
disulfide bonds to GSH. In addition, DTX was expected to kill the bulk and chemo-sensitized
tumor cells. Thus, in vitro release behavior of DTX from DTX/P-RUB micelles was also
determined. As shown in Figure 3.5 C, the incubation of micelles with 10 mM GSH at pH 5
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resulted in 95% of DTX release within 8 h and 99% of DTX after 12 h, while the intracellular
circumstance (10 mM GSH) or acidic endocytic vesicles (pH = 5-6) individually

reductive

facilitates DTX release, with 87% and 91%, respectively. Without these triggers, 72% of DTX was
released at pH 7.4 after 24 h. It again indicates the expansion and disassembly of micelles induced
by disulfide bond cleavage and protonation of tertiary amines can accelerate drug release regardless
of its delivery by encapsulation or conjugation. We also determined DTX release from
nonresponsive P-RUB micelles at pH7.4 and 5. There was little influence of pH on its release from
these micelles (Figure 3.5 D).
3.4.4 Cellular uptake and intracellular distribution
To determine the cellular uptake and monitor subcellular distribution of P-RUB, Cy5.5 labeled
P-RUB and Cy5.5 labeled nonresponsive P-RUB were synthesized (Figure 3.3 and 3.6) and further
made into micelles in aqueous solution. As the results from confocal laser scanning microscopic
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(CLSM) shown in Figure 3.7 A, Cy5.5-labeled P-RUB micelles were efficiently taken up by
DU145-TXR and PC3-TXR cells, with uniform intracellular distribution in both cell lines. We also
determined the cellular uptake of Cy5.5 labeled non-responsive P-RUB micelles and found to be
poorly taken up by these cell types, as evidenced by weaker fluorescent staining (Figure 3.7 B).
Through the observation of micelles and intracellular lysosomes by lysotracker staining, we found
that Cy5.5-labeled P-RUB micelles were mostly endocytosed (Figure 3.7 C). Furthermore, some
polymers have escaped from the lysosome after 6 h.
3.4.5 In vitro antitumor activity
The cytotoxicity of DTX, RUB, P-RUB and DTX/P-RUB micelles and non-responsive
DTX/P-RUB were evaluated on DU145-TXR and PC3-TXR by 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) assay. As shown in Figure 3.8 A, comparable growth
inhibition capability of free DTX, RUB, P-RUB, nonresponsive P-RUB and nonresponsive
DTX/P-RUB micelles were observed on PC3-TXR cells, and 10 μM of P-RUB was needed in
the combination therapy for the treatment of DU145-TXR cells to achieve the same
proliferation inhibitory effect as 5 μM of free RUB did. Though RUB inhibited the
proliferation of DU145-TXR cells by 40%, we noticed that DTX, P-RUB alone, nonresponsive P-RUB did not show much antitumor effects on PC3-TXR and DU145-TXR cells
and, indicating the combination therapy of DTX and P-RUB can efficiently overcome the
chemoresistance of prostate cancer cell lines by the upregulation of miR-34a in the cancer
cells. We also determined the effect of non-responsive DTX/P-RUB micelles on the cell
viability of DU145, PC-3, DU145-TXR and PC3-TXR cells and found dose-dependent
inhibition of these cell proliferation on PC-3 and DU145 cells and limited inhibitory effect on
DU145-TXR and PC3-TXR cells (Figure 3.8 A).
To further demonstrate the usefulness of dual responsive P-RUB micelles, we used buthionine
sulphoxime (BSO) to deplete intracellular GSH and Nigericin to inhibit the endosomal
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acidification. As shown in Figure 3.8 A, blocking of both GSH and acidification of endosomes
significantly decreased the cell killing ability of DTX/P-RUB micelles on PC3-TXR and DU145TXR cells. Cell viability was higher when GSH was blocked by buthionine sulphoximine than
that by Nigericin (Figure 3.8 A).
To better simulate the complex tumor microenvironment, we generated hanging top 3D model
spheroids of DU145-TXR cells. There was significant reduction in spheroid size when the tumor
spheroids were treated with DTX, P-RUB and DTX/P-RUB micelles, with almost complete
disruptions of the spheroids with DTX/P-RUB micelle treatment. This suggests DTX/P-RUB

Figure 3.1348
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Figure 3.1591

micelles were more potent in inhibiting the cell proliferation than single treatment compared to
non-treated control (Figure 3.8 B). We also determined the effect of nonresponsive P-RUB and
DTX/P-RUB micelles on these tumor spheroids and found relatively weaker disruption of tumor
spheroids.

3.4.6 Effect on cell cycle arrest and CSC proliferation
Since the combination therapy of DTX and P-RUB showed good potency in inhibiting the
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proliferation of DU145-TXR and PC3-TXR cells, we determined how the formulation regulates
the cell cycle of these cell lines. As shown in Figure 3.9 A, major population of the cells (∼55%)
was in G0/G1 phase in the control, DTX and P-RUB treated groups. Meanwhile, we also noticed
that the cells at S phase increased a little (∼5%) with the treatment of P-RUB micelles. Treatment
with DTX/P-RUB micelles significantly increased the cell percentage at G2/ M phase in DU145TXR and PC3-TXR cells (from ∼22% to ∼60%), indicating P-RUB micelles can chemo-sensitize
DU145-TXR and PC3-TXR cells towards DTX, resulting in subsequent cell killing by DTX.

This resemble the results we observed from DTX treated DU145 and PC3 cells that the
major population (almost 70%) of these taxane sensitive cells was arrested in the G2/M phase
(Figure 3.9 A).
As the CSCs contribute to chemoresistance of prostate cancer, efficacy in the inhibition of
the ALDH-1 high subpopulation by P-RUB micelles was determined by Aldeflour staining of
ALDH+ cells. The ALDH-1 high subpopulation constitutes approximately 17.4% and 32.9%
of the whole cells on DU145-TXR and PC3-TXR cells (Figure 3.9 B). The treatment of PRUB micelles on these cell lines successfully decreased the ALDH-1-high subpopulation in a
dose dependent manner to 8.9% and 24%, which suggests that P-RUB micelles can reverse the
chemoresistance of prostate cancer cells against DTX with increased CSC proliferation. In
addition, DTX/P-RUB micelles can further decrease the ALDH1-high subpopulation of
DU145-TXR cells to 4.5%. Collectively, our results demonstrated that combination therapy of
DTX and P-RUB significantly reversed chemoresistance and decreased the CSC population
of drug resistant prostate cancer cells.

3.4.7 miR-34a and protein regulation by P-RUB micelles
Since RUB is a miR-34a activator, P-RUB is expected to upregulate miR-34a in the tumor cells.
Therefore, we treated DU145-TXR and PC3-TXR cell lines with P-RUB micelles and determined
their effect by RT- PCR (Figure 3.9 C). P-RUB micelles could successfully upregulate the level
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Figure 3.1834 Biodistribution of micelles in vivo.

of miR-34a on both cell lines in a dose dependent manner. Increasing RUB concentration resulted
in significant increase in miR-34a expression on both cell lines compared to the group without
treatment of P-RUB micelles and it is much more significant on PC3-TXR (Figure 3.9 C).
Afterwards, we evaluated the expression of proteins relative to miR-34a following the treatment of
P-RUB micelles. Compared to the control group, miR-34a inducers, Elk1 and p73 were upregulated
on both cell lines. On the other hand, drug resistance and tumor growth related SIRT1 expression
was repressed and the level of apoptotic Bax protein was increased by P-RUB micelles (Figure 3.9
D). The results are consistent with the upregulation of miR-34a in DU145-TXR and PC3-TXR
from RT- PCR. In other words, P-RUB micelles first upregulated the expression of Elk1 and p73,
which then induced miR-34a expression in the tumor cells.
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3.4.8 Biodistribution
The tumor targeting ability of DTX/P-RUB micelles was studied on orthotopic PC3-TXR
tumor bearing nude mice. The Cy5.5 labeled DTX/P-RUB micelles were first injected into
mice via the tail vein and time dependent fluorescence emission images of Cy5.5 at 710 nm
were taken at different time points: 0, 1, 3, 6, 12, 24 and 48 h. Fluorescent signals were
observed at 1 h post injection (Figure 3.10). As time elapsed, the fluorescent intensity
increased with time and then reached the maximum at 24 h at the tumor sites post
administration. A relatively high photon flux was still recorded at 48 h post injection despite
of metabolism and clearance. Thereafter, a further tissue distribution of DTX/P- RUB micelles
was studied by ex vivo imaging of tumors and other major organs such as heart, lung, liver,
spleen and kidney. As shown in Figure 3.10 B and C, DTX/P-RUB micelles showed more
accumulation in the tumor, liver and kidneys than in spleen, heart and lungs, suggesting that
DTX/ P-RUB micelles can
efficiently deliver DTX and
RUB to the orthotopic prostate
tumors

after

systemic

administration. Since Cy5.5 was
chemically linked to P-RUB but
not to RUB, we could not carry
out the quantitative analysis of
free RUB and Cy5.5 labeled PRUB using a fluorimeter at 24 h
and

48

h

administration.

post

systemic

Instead,

Figure 3.2075

we

determined RUB concentration
in the tumor after extraction
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using LC/MS/MS. The results shown in Figure 3.11 correlate well with fluorescence analysis
shown in Figure 3.10: P-RUB micelles preferentially accumulated in the tumor. RUB
concentration from Cy5.5 labeled P-RUB micelle treated tumor sample was much higher than that
from the free drug treated tumor samples, possibly due to the rapid distribution, elimination and
metabolism of chalcone and its derivatives including RUB. Thus, our micelles not only efficiently
deliver drugs to the tumor and release the drugs upon stimulation by pH and GSH, but also protect
RUB from metabolism before it reaches the tumor.

Figure 3.2298

Antitumor efficacy in vivo.
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3.4.9 In vivo anticancer efficacy
Inspired by the ability of DTX/P-RUB micelles in combating TXR, the in vivo anticancer
efficacy of DTX/P-RUB micelles was determined on PC3-TXR orthotopic prostate tumor bearing
nude mice. Various formulations (PBS, DTX + RUB, P-RUB micelles, DTX/P-RUB micelles,
DTX/PEG-PCD micelles and nonresponsive DTX/P-RUB micelles) were intravenously injected
into mice every other 2 days for 18 days. As shown in Figure 3.12 A and B, C, rapid tumor growth
in mice treated with free drugs due to their rapid clearance from the body. The single treatment of
P-RUB micelles failed to inhibit the tumor growth, which is consistent with the results obtained in
vitro. However, the average tumor volume in DTX/P-RUB micelles treated mice were the smallest
compared to the rest of the groups at the end of treatment (P < 0.05), showing the highest antitumor
activity against PC3-TXR cells. DTX/PEG-PCD micelles did not show any therapeutic effect on
PC3-TXR tumor growth. However, nonresponsive DTX/P-RUB micelles could decrease the tumor
burden of mice, but not as effective as the dual responsive DTX/P-RUB micelles. It can be
contributed to several reasons, including its efficient delivery of DTX and RUB to tumor sites as
well as GSH and pH triggered release of DTX and RUB after endocytosis. Among all the groups,
we noted that the free drug group caused obvious body weight loss due to the severe systemic
toxicity of DTX, not RUB. miR-34a was greatly upregulated in P-RUB micelles and DTX/P-RUB
micelles treated groups and this was supported by the downregulation of SIRT1 in tumor tissues in
immunohistochemical and western blot analysis (Figure 3.13 A and B). Meanwhile, the level of
cleaved caspase-3 that indicates cell apoptosis and proliferation was significantly increased and the
number of Ki-76 positive proliferating tumor cells was decreased when treated with DTX/P-RUB
micelles (Figure 3.13 C). We also quantified the % of SIRT1, Ki-67 and cleaved caspase-3
positive cells by ImageJ. The % of SIRT1 and Ki-67 positive cells was statistically lower, but %
of cleaved caspase-3 positive cells was higher in the tumor samples of mice treated with DTX/PRUB micelles compared to those treated with the mixture of DTX and RUB or P-RUB treated
groups (Figure 3.13 D).
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Figure 3.2459

In DTX/P-RUB micelles treated group, fewer cells were observed in hematoxylin and eosin
(H&E) staining of the tumors, and there is no obvious histopathological abnormality in other organs
such as kidney, heart, lung and heart in all groups (Figure 3.14). These results collectively
indicate that DTX/P-RUB micelles can effectively suppress the tumor progression while
reducing the systemic toxicity of DTX.

3.5 Discussion
While chemotherapeutic drugs such as DTX and PTX are effective in killing proliferating
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Figure 3.2522 Representative histological images from retrieved tissues.

prostate cancer cells, they fail to inhibit CSC proliferation owing to multidrug resistance (MDR)
[1,51,52]. Thus, cancer patients face a big threat from chemoresistance that ultimately leads to
subsequent metastasis and relapse. The complicated mechanism of chemoresistance lies on drug
segregation [53–55], altered cellular pathway [56–58], insufficient drug influx due to high
expression of P- glycoprotein (P-gp) for drug efflux [59], dysregulation of miRNAs [15], reduced
apoptosis and proliferation of CSCs [60,61]. miR-34a and its downstream targets (SIRT1 [62],
LEF1 [63], TCF7 [64], AR [65] and Notch-1 [66]) have been found to influence CSC proliferation,
metastasis and chemoresistance of cancers. Considering the challenges faced by nucleic acid-based
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drugs, including potential immunogenicity, in vivo instability, off target effect and high
cytotoxicity [15,17], small molecules having similar function as miR-34a are often regarded as
better candidates for cancer treatment due to their stability and ease of production. Thus, the
simultaneous administration of a recently discovered small molecule miR-34a activator named
RUB and DTX are expected to synergistically and efficiently inhibit tumor growth by killing both
CSCs and bulk tumor cells. Although the hydrophobicity of the drugs is the major obstacle in
application, the delivery by nanocarriers can effectively improve their aqueous solubility,
enhances their therapeutic efficacy and reduces their adverse toxicities. However, recent need
to improve the biological specificity in therapy has driven the efforts to the development of
nanoparticles that respond to pH alteration, redox potential and reactive oxygen species (ROS)
[67,68] through the spatiotemporal control of drug delivery. Despite great efforts devoted to
the development of nanoparticles to overcome chemoresistance and most of them focused on
how to increase of the accumulation of drugs by avoiding efflux by P-gp [25,69], including
the application of Pluronics [70], not much attention has been paid to develop multifunctional
pH-responsive micelles that can regulate miRNA expression by small molecule drugs while
bypassing P-gp at the same time.
In this study, we developed dual responsive polymer conjugated RUB and DOX encapsulated
(DOX/P-RUB) micelles that respond to intracellular pH and GSH levels to accelerate and maximize
the drug release. We demonstrated that P-RUB micelles were able to upregulate miR-34a
expression in p53 null prostate cell lines, PC3-TXR and DU154-TXR, through upregulating ElK1
and p73 expression (Figure 3.9). RUB release was accelerated by addition of GSH within 24 h
which attributed to the cleavage of disulfide bond, whereas less than 5% of RUB was detected
without GSH (Figure 3.5). We also synthesized non- responsive P-RUB by conjugating RUB and
dodecanol to the pendant carboxylic acid groups of PEG-PCC. There was little release of RUB
from these nonresponsive micelles at pH 7.4 and 5. Moreover, change in pH had little influence on
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DTX release from these nonresponsive micelles (Figure 3.5).
There was significant expansion and dissociation of dual responsive P-RUB micelles at pH 5
(Figure 3.4). Meanwhile, DIPAE plays an important role in other aspects as well: 1) at pH 7.4, the
positively charged con- jugated DIPAE (pKa: ∼8.5) interact with negatively charged carboxylic
acids (pKa: ∼5), leading to stabilization of micellar structure; 2) due to the increased degree of
protonation of tertiary amine at acidic pH value, P-RUB micelles expanded and dissociated,
resulting in rapid drug release (Figure 3.5). In addition, DTX encapsulated P-RUB micelles
(DTX/P- RUB) were proven to efficiently inhibit the cell proliferation in 2D and 3D models
(Figure 3.8).
We previously reported the co-delivery of PTX and RUB using poly (ethylene glycol)-blockpoly(2-methyl-2-carboxyl-propylene carbonate- graft-dodecanol (PEG-PCD) micelles for the
treatment of TXR prostate cancer. In our previous study, RUB was physically encapsulated into
PEG-PCD copolymeric micelles with poor drug loading, and release of both PTX and RUB was
dependent on hydrophobic interaction and their release was mainly via passive diffusion. In
contrast, in the present study the therapeutic effect of DTX and RUB depends on pH-dependent
rapid drug release due to protonation and cleavage of disulfide bond. Moreover, RUB is covalently
conjugated to the polymer with higher drug loading.
P-RUB studied here is a copolymer that is not only able to encapsulate other hydrophobic drugs,
but also responsive to pH value and elevated intracellular GSH level to ensure rapid rate to reach
the therapeutic window of drugs. Moreover, the similar idea can be applied to other delivery
systems. For example, the reactive oxygen species (ROS) responsive targeting delivery system can
be constructed by conjugating other drugs with thioether linkers and specific ligands to improve
the tumor specificity. Therefore, the nontoxic polycarbonate with pendent carboxylic acid platform
constructed here has the potential to come up with a pool of promising strategies that increase
specificity and efficacy of chemotherapy and reduce their cytotoxicity to treat cancer and to other
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analogous pathologies.
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4.1 Conclusions
With more and more NDDS being approved by FDA for clinical use and clinical trials, NDDS
show great potentials of in treatment or diagnosis of various diseases [1, 2]. The interest in the
development and application of NDDS in cancer treatment largely lie in its appealing features.
NDDS solve some long existing problems in pharmaceutics: 1) potent drugs but fail to meet the
Lipski’ rule of five small molecule can be further evaluated for efficacy; 2) Blood circulation time
of drugs can be elongated; 3) undesirable toxicity and potential off-target effect can be avoided.
Nevertheless, there is a need for the development of smart NDDS for delivery of chemotherapeutic
agents including genes and hydrophobic drugs and these smart NDDS can release the cargos in a
temporal and spatial manner for target therapy.
Benefiting from recent advances in material science, we constructed a cationic NDDS with
pendent arylboronic acids for codelivery of gene and drug. The NDDS exhibited high drug loading
capability for volasertib with an alkyl amino group due to donor-receptor interaction and low N/P
value (16:1) for complexation of miR-34a. Upon oxidization by H2O2, drug and gene were
simultaneously released and exhibited synergistic effect in inhibition of tumor growth in vitro and
in vivo.
Based on the discovery for the treatment of taxane resistant prostate cancer in our laboratory
and other laboratory, we determined to conjugate the highly hydrophobic and rigid drug named
rubone to the biocompatible polycarbonates to solve the low drug loading. With this strategy, up to
40% of drug loading can be achieved. Due to the ionizable tertiary amine group under acidic
environment, the polymers expanded to facilitate the release of both drugs, DTX and conjugated
rubone, from the micelles. Compared to non-responsive drug conjugate, the DTX/P-RUB
significantly inhibit the growth of taxane resistant prostate cancer on nude mice.
Taken all together, the resultant NDDS mediated combination therapy of drug/gene or
drug/drug among which one can induce the expression of tumor suppressor genes exhibited a
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synergistic effect on the inhibition of tumor growth for efficacious treatment of pancreatic cancer
or chemo-resistant prostate cancer. In addition, the strategies used in the projects provides a
versatile approach for loading highly hydrophobic drugs, through donor-receptor interaction
between alkyl amine group and arylboronic acid or conjugation with a disulfide containing linker.
We believe the results from the projects will positively affect advances in smart NDDS
development for the treatment of tumors.

4.2 Challenges and perspective
Despite the great process in the treatment of cancers using NDDS, we need to realize there are still
some challenges ahead: 1) the complexity and heterogeneity of tumor make it hard for NDDS to
reach to core area that locate it far from the abnormal vasculature; 2) burst and undesirable drug
release of encapsulated small molecule drugs may lower the specificity and increase the adverse
effect of NDDS, given that controlled drug release of some smart NDDS depends on stimulitriggered degradation of polymers while the drug loading still relies on the weak hydrophobic
interaction; 3) traditional methods to prepare NDDS can result in high polydispersity, making it
hard for quality control.
One solution to the first concern is to use targeting ligands. Recent studies reported the
conjugation of tumor-homing peptide, (CRGDK/RGPD/EC) (iRGD) onto the surface of NDDS can
bind to tumor vessels and spread into the extravascular tumor parenchyma, in sharp contrast to the
conventional RGD peptides that only deliver the cargo to the blood vessels [3-5].
The second challenge can be solved by conjugating the drug to the backbone of polymer as we
did in the second work if the drugs have available functional groups, including -NH2, -OH and CHO [6-8]. For those drugs without functional groups for conjugation, the strong ionic interaction
is also a good option for drug encapsulation, in light of gene delivery and the donor-receptor
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interaction for drug encapsulation [9, 10]. Meanwhile, more strong bonds await being found and
applied to physically load the drugs.
The emergence of microfluidic technologies can achieve high speed and good reproducibility
in preparing NDDS with narrow size distribution and tunable physical and chemical characteristics
[11-13]. Another nano-technique named particle replication in non-wetting template (PRINT) also
allow the preparation of monodispersed NDDS with control size, shape and surface property [14,
15].
Taken together, smart NDDS with monodispersity and good quality control could be
synthesized in the near future and can potentially achieve deep penetration and even more precise
onsite drug release in order to kill the cancer cell locating in the interior of tumors and reduce the
undesirable toxicity.
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